<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CEP</journal-id>
<journal-id journal-id-type="hwp">spcep</journal-id>
<journal-title>Cephalalgia</journal-title>
<issn pub-type="ppub">0333-1024</issn>
<issn pub-type="epub">1468-2982</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0333102412475234</article-id>
<article-id pub-id-type="publisher-id">10.1177_0333102412475234</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Special Issue Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Pearls and pitfalls in human pharmacological models of migraine: 30 years' experience</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Ashina</surname><given-names>Messoud</given-names></name>
<xref ref-type="corresp" rid="corresp1-0333102412475234"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Hansen</surname><given-names>Jakob Møller</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Olesen</surname><given-names>Jes</given-names></name>
</contrib>
</contrib-group>
<aff id="aff1-0333102412475234">Danish Headache Center and Department of Neurology, Glostrup Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark</aff>
<author-notes>
<corresp id="corresp1-0333102412475234">Messoud Ashina, Danish Headache Center and Department of Neurology, Glostrup Hospital, Ndr. Ringvej 67, Building 14, DK-2600 Glostrup, Denmark. Email: <email>ashina@dadlnet.dk</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>33</volume>
<issue>8</issue>
<issue-title>Special Issue on Pearls and Pitfalls in Headache Research</issue-title>
<fpage>540</fpage>
<lpage>553</lpage>
<history>
<date date-type="received"><day>2</day><month>8</month><year>2012</year></date>
<date date-type="rev-recd"><day>15</day><month>11</month><year>2012</year></date>
<date date-type="rev-recd"><day>2</day><month>12</month><year>2012</year></date>
<date date-type="accepted"><day>20</day><month>12</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© International Headache Society 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">International Headache Society</copyright-holder>
</permissions>
<abstract>
<p>In vitro studies have contributed to the characterization of receptors in cranial blood vessels and the identification of new possible anti-migraine agents. In vivo animal models enable the study of vascular responses, neurogenic inflammation, peptide release and genetic predisposition and thus have provided leads in the search for migraine mechanisms. All animal-based results must, however, be validated in human studies because so far no animal models can predict the efficacy of new therapies for migraine.</p>
<p>Given the nature of migraine attacks, fully reversible and treatable, the headache- or migraine-provoking property of naturally occurring signaling molecules can be tested in a human model. If such an endogenous substance can provoke migraine in human patients, then it is likely, although not certain, that blocking its effect will be effective in the treatment of acute migraine attacks.</p>
<p>To this end, a human in vivo model of experimental headache and migraine in humans has been developed. Human models of migraine offer unique possibilities to study mechanisms responsible for migraine and to explore the mechanisms of action of existing and future anti-migraine drugs. The human model has played an important role in translational migraine research leading to the identification of three new principally different targets in the treatment of acute migraine attacks and has been used to examine other endogenous signaling molecules as well as genetic susceptibility factors. New additions to the model, such as advanced neuroimaging, may lead to a better understanding of the complex events that constitute a migraine attack, and better and more targeted ways of intervention.</p>
</abstract>
<kwd-group>
<kwd>Migraine</kwd>
<kwd>human models of migraine</kwd>
<kwd>drug targets</kwd>
<kwd>migraine provocation</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0333102412475234" sec-type="intro"><title>Introduction</title>
<p>The recent tremendous progress in headache medicine and research is the result of translational work, taking ideas from bedside to bench – and back. Animal experiments are necessary to separate and analyze different components of the migraine attack such as the transmission of nociceptive impulses, vascular reactions and the role of inflammatory mechanisms. However, an animal model that is identical or almost identical to human migraine has not yet been developed, and eventually all predictions from animal studies need to be confirmed in a suitable human model.</p>
<p>Over the last 30 years the systematic use of human models of migraine has provided crucial data on mechanisms underlying migraine pathophysiology. Human experimental models of migraine allow the study of the pathophysiological events during an attack. This is not always possible during spontaneous migraine attacks because disability inhibits the migraineurs from traveling to the hospital. Furthermore, experimental models allow the study of migraine attacks under carefully controlled and monitored conditions, a definitive advantage from a scientific viewpoint (<xref ref-type="fig" rid="fig1-0333102412475234">Figure 1</xref>). The model can therefore be used to identify and validate potential drug targets and study their effect in the ideal model: The patient. In the model, the headache-inducing effects of all naturally occurring endogenous substances can be studied. If a substance is found to induce migraine, antagonists to that specific molecule or receptor can then subsequently be studied.
<fig id="fig1-0333102412475234" position="float"><label>Figure 1.</label><caption><p>The human provocation model, modified from Olesen et al. (127) with permission. In the main version of this model, patients with migraine are randomly allocated to receive intravenous infusion (over 25 min) of ‘target substance’ or placebo (isotonic saline) in a double-blind, crossover design. Headache intensity is recorded on a verbal rating scale from 0 to 10 (0, no headache; 1, a very mild headache (including a feeling of pressing or throbbing); 5, moderate headache; 10, worst imaginable headache). The following haemodynamic variables are recorded at pre-defined intervals: mean velocity of blood flow in the middle cerebral artery by transcranial Doppler with hand-held 2-MHz probes; diameter of the frontal branch of the superficial temporal artery by a high-resolution ultrasonography unit. With the addition of other imaging modalities such as high-field magnetic resonance imaging (MRI) angiography, even more detailed information can be collected on the vascular response of the cephalic circulation. Heart rate and blood pressure are measured continuously throughout the study. The subjects are asked to complete a headache diary every hour until 10 hours after discharge. The diary included headache characteristics and accompanying symptoms necessary to classify the headache according to the second edition of the International Classification of Headache Disorders (ICHD-II).</p>
<p>CGRP: calcitonin gene-related peptide; PACAP: pituitary adenylate cyclase activating polypeptide.</p></caption><graphic xlink:href="10.1177_0333102412475234-fig1.tif"/>
</fig></p>
<p>Here we present pearls and pitfalls from the history of human provocation experiments. A number of pharmacological substances have been studied in humans. We will critically review the available human studies, with special emphasis on glyceryl trinitrate (GTN) since this has been studied in most detail.</p>
</sec>
<sec id="sec2-0333102412475234"><title>The GTN model</title>
<p>It has been known for more than 100 years that GTN induces headache (<xref ref-type="bibr" rid="bibr1-0333102412475234">1</xref>,<xref ref-type="bibr" rid="bibr2-0333102412475234">2</xref>). GTN is a donor of nitric oxide (NO) and its headache-inducing effect was demonstrated in a provocation experiment (<xref ref-type="bibr" rid="bibr3-0333102412475234">3</xref>).</p>
<sec id="sec3-0333102412475234"><title>Pearls</title>
<p>The important details of GTN-induced headache, such as headache time profile, pain characteristics and accompanying symptoms, were carefully investigated. Patients with migraine were hypersensitive to NO, i.e. migraineurs developed significantly stronger headache after GTN infusion than healthy subjects (<xref ref-type="bibr" rid="bibr4-0333102412475234">4**</xref>). Furthermore, migraine without aura (MO) patients not only developed an immediate headache during GTN infusion but 80% of patients several hours after stopping the infusion developed a delayed headache fulfilling International Classification of Headache Disorders (ICHD-II) criteria for a migraine attack (<xref ref-type="bibr" rid="bibr5-0333102412475234">5</xref>,<xref ref-type="bibr" rid="bibr6-0333102412475234">6</xref>) (<xref ref-type="fig" rid="fig2-0333102412475234">Figure 2</xref>). These data are based on intravenous GTN administration. Other routes of GTN administration (e.g. sublingual) can be used, but results are more variable and the rate of migraine induction is reduced (<xref ref-type="bibr" rid="bibr7-0333102412475234">7</xref>); see <xref ref-type="table" rid="table1-0333102412475234">Table 1(a)</xref>.
<fig id="fig2-0333102412475234" position="float"><label>Figure 2.</label><caption><p>An illustrative example of the headache response curve after provocation, adapted from Thomsen et al. (6) with permission. The glyceryl trinitrate (GTN) experimental model of migraine showed that in migraine patients infusion of GTN causes an immediate headache during the infusion and a delayed headache that is maximal around six to seven hours after the infusion. This delayed headache has the characteristics of typical attacks of migraine without aura.</p></caption><graphic xlink:href="10.1177_0333102412475234-fig2.tif"/>
</fig>
<table-wrap id="table1-0333102412475234" position="float"><label>Table 1(a).</label><caption><p>Percentages of migraine patients reporting migraine-like attacks in experimental studies.</p></caption>
<graphic alternate-form-of="table1-0333102412475234" xlink:href="10.1177_0333102412475234-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th colspan="2">Compound</th>
<th>Dose</th>
<th>Migraine-like attacks</th>
<th>Ref</th>
</tr></thead>
<tbody align="left">
<tr>
<td rowspan="4">Glyceryl trinitrate (GTN)</td>
<td rowspan="1">Migraine with aura</td>
<td>Intravenous 0.5 µg/kg/min</td>
<td>50%–67%</td>
<td>(<xref ref-type="bibr" rid="bibr12-0333102412475234">12**</xref>,<xref ref-type="bibr" rid="bibr105-0333102412475234">105</xref>)</td>
</tr>
<tr>
<td>Sublingual 0.9 mg</td>
<td>40.9%</td>
<td>(<xref ref-type="bibr" rid="bibr7-0333102412475234">7</xref>)</td>
</tr>
<tr>
<td rowspan="1">Migraine without aura</td>
<td>Intravenous 0.5 µg/kg/min</td>
<td>80%–83%</td>
<td>(<xref ref-type="bibr" rid="bibr6-0333102412475234">6</xref>,<xref ref-type="bibr" rid="bibr12-0333102412475234">12**</xref>)</td>
</tr>
<tr>
<td>Sublingual 0.9 mg</td>
<td>82.1%</td>
<td>(<xref ref-type="bibr" rid="bibr7-0333102412475234">7</xref>)</td>
</tr>
<tr>
<td>Hemiplegic migraine</td>
<td>Intravenous 0.5 µg/kg/min</td>
<td>12.5%–30%</td>
<td>(<xref ref-type="bibr" rid="bibr118-0333102412475234">118</xref>,<xref ref-type="bibr" rid="bibr122-0333102412475234">122</xref>,<xref ref-type="bibr" rid="bibr123-0333102412475234">123</xref>)</td>
</tr>
<tr>
<td colspan="2" rowspan="2">Histamine</td>
<td>Intravenous 0.5 µg/kg/min</td>
<td>70%</td>
<td>(<xref ref-type="bibr" rid="bibr48-0333102412475234">48</xref>)</td>
</tr>
<tr>
<td>Intravenous 0.1 mg</td>
<td>78%</td>
<td>(<xref ref-type="bibr" rid="bibr45-0333102412475234">45</xref>)</td>
</tr>
<tr>
<td>Arterial 0.1 mg (carotid)</td>
<td>77%</td>
<td>(<xref ref-type="bibr" rid="bibr45-0333102412475234">45</xref>)</td>
</tr>
<tr>
<td colspan="2">Sildenafil</td>
<td>100 mg per os</td>
<td>83%</td>
<td>(<xref ref-type="bibr" rid="bibr71-0333102412475234">71**</xref>)</td>
</tr>
<tr>
<td colspan="2">Dipyridamole</td>
<td>Intravenous 0.142 mg/kg/min</td>
<td>50%</td>
<td>(<xref ref-type="bibr" rid="bibr73-0333102412475234">73</xref>)</td>
</tr>
<tr>
<td rowspan="2">Calcitonin gene-related peptide (CGRP)</td>
<td>Migraine with aura</td>
<td>Intravenous 1.5 µg/min</td>
<td>57%</td>
<td>(<xref ref-type="bibr" rid="bibr61-0333102412475234">61</xref>)</td>
</tr>
<tr>
<td>Migraine without aura</td>
<td>Intravenous 2 µg/min</td>
<td>33%–75%</td>
<td>(<xref ref-type="bibr" rid="bibr60-0333102412475234">60</xref>)</td>
</tr>
<tr>
<td>Hemiplegic migraine</td>
<td>Intravenous 1.5 µg/min</td>
<td>9%–22%</td>
<td>(<xref ref-type="bibr" rid="bibr116-0333102412475234">116**</xref>,<xref ref-type="bibr" rid="bibr117-0333102412475234">117</xref>)</td>
</tr>
<tr>
<td colspan="2">Vasoactive intestinal peptide (VIP)</td>
<td>Intravenous 8 pmol/kg/min</td>
<td>0%</td>
<td>(<xref ref-type="bibr" rid="bibr83-0333102412475234">83</xref>)</td>
</tr>
<tr>
<td colspan="2">Pituitary adenylate cyclase-activating polypeptide (PACAP-38)</td>
<td>Intravenous 10 pmol/ kg/min</td>
<td>66%</td>
<td>(<xref ref-type="bibr" rid="bibr85-0333102412475234">85**</xref>)</td>
</tr>
<tr>
<td rowspan="1">Prostaglandins</td>
<td>Prostaglandin E2</td>
<td>Intravenous 0.4 µg/kg/min</td>
<td>58%</td>
<td>(<xref ref-type="bibr" rid="bibr95-0333102412475234">95**</xref>)</td>
</tr>
<tr>
<td>Prostaglandin I2</td>
<td>Intravenous 10 ng/kg/min</td>
<td>50%</td>
<td>(<xref ref-type="bibr" rid="bibr92-0333102412475234">92</xref>)</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table2-0333102412475234" position="float"><label>Table 1(b).</label><caption><p>Percentages of healthy volunteers reporting headache in experimental studies.</p></caption>
<graphic alternate-form-of="table2-0333102412475234" xlink:href="10.1177_0333102412475234-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="1">Compound</th>
<th rowspan="1">Dose</th>
<th colspan="2">Headache</th>
<th rowspan="1">Ref</th>
</tr>
<tr><th>Immediate</th>
<th>Delayed</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Glyceryl trinitrate (GTN)</td>
<td>Intravenous 0.25–2.0 µg/kg/min</td>
<td>80%–90%</td>
<td>40%–75%</td>
<td>(<xref ref-type="bibr" rid="bibr3-0333102412475234">3</xref>,<xref ref-type="bibr" rid="bibr4-0333102412475234">4**</xref>,<xref ref-type="bibr" rid="bibr21-0333102412475234">21</xref>)</td>
</tr>
<tr>
<td>Histamine</td>
<td>Inhalation, 2–64 mg/ml</td>
<td>47%</td>
<td>53%</td>
<td>(<xref ref-type="bibr" rid="bibr124-0333102412475234">124</xref>)</td>
</tr>
<tr>
<td>Sildenafil</td>
<td>100 mg per os</td>
<td>∼60%</td>
<td>∼60%</td>
<td>(70)</td>
</tr>
<tr>
<td>Dipyridamole</td>
<td>Intravenous 0.142 mg/kg/min</td>
<td>66%</td>
<td>41%</td>
<td>(<xref ref-type="bibr" rid="bibr125-0333102412475234">125</xref>)</td>
</tr>
<tr>
<td>Calcitonin gene-related peptide (CGRP)</td>
<td>Intravenous 1.5 µg/min</td>
<td>50%</td>
<td>30%</td>
<td>(<xref ref-type="bibr" rid="bibr63-0333102412475234">63</xref>)</td>
</tr>
<tr>
<td>Vasoactive intestinal peptide (VIP)</td>
<td>Intravenous 8 pmol/kg/min</td>
<td>41%</td>
<td>25%</td>
<td>(<xref ref-type="bibr" rid="bibr82-0333102412475234">82</xref>)</td>
</tr>
<tr>
<td>Pituitary adenylate cyclase-activating polypeptide (PACAP-38)</td>
<td>Intravenous 10 pmol/ kg/min</td>
<td>89%</td>
<td>100%</td>
<td>(<xref ref-type="bibr" rid="bibr85-0333102412475234">85**</xref>,<xref ref-type="bibr" rid="bibr86-0333102412475234">86</xref>)</td>
</tr>
<tr>
<td>Prostaglandin E2</td>
<td>Intravenous 0.4 µg/kg/min</td>
<td>75%–100%</td>
<td>12%–45%</td>
<td>(<xref ref-type="bibr" rid="bibr91-0333102412475234">91</xref>,<xref ref-type="bibr" rid="bibr98-0333102412475234">98</xref>)</td>
</tr>
<tr>
<td>Prostaglandin I2</td>
<td>Intravenous 10 ng/kg/min</td>
<td>92%</td>
<td>36%</td>
<td>(<xref ref-type="bibr" rid="bibr94-0333102412475234">94</xref>)</td>
</tr>
</tbody>
</table>
</table-wrap>
</p>
<p>Interestingly, positron-emission tomography (PET) studies showed brainstem activation during GTN-induced attacks (<xref ref-type="bibr" rid="bibr8-0333102412475234">8</xref>,<xref ref-type="bibr" rid="bibr9-0333102412475234">9</xref>), exactly as reported during spontaneous migraine attacks (<xref ref-type="bibr" rid="bibr10-0333102412475234">10</xref>,<xref ref-type="bibr" rid="bibr11-0333102412475234">11**</xref>). Furthermore, GTN induces premonitory symptoms (<xref ref-type="bibr" rid="bibr12-0333102412475234">12**</xref>) and hypothalamic activation (<xref ref-type="bibr" rid="bibr13-0333102412475234">13</xref>), thus providing an understanding of symptoms also reported during spontaneous migraine attacks (<xref ref-type="bibr" rid="bibr14-0333102412475234">14</xref>).</p>
<p>Collectively, these studies clearly suggest that GTN may trigger a genuine migraine attack in migraine sufferers and that NO plays a crucial role in migraine pathogenesis.</p>
<p>Arterial dilatation may cause headache (<xref ref-type="bibr" rid="bibr15-0333102412475234">15</xref>), and GTN infusion causes a more pronounced dilation of extra- and intracerebral arteries in migraine patients than in controls (<xref ref-type="bibr" rid="bibr16-0333102412475234">16</xref>); see <xref ref-type="table" rid="table4-0333102412475234">Table 3</xref>. Long-term administration of isosorbide-5-mononitrate, a long-acting NO donor, induced vasodilation of the superficial temporal artery (STA) attenuated over seven days, which correlated with the disappearance of NO-induced headache (<xref ref-type="bibr" rid="bibr17-0333102412475234">17</xref>). This was not observed for the middle cerebral artery (MCA), suggesting an important role for extracerebral arteries in GTN-induced headache.
</p>
<p>The onset of the immediate GTN-induced headache in healthy volunteers is correlated to dilation of the MCA (<xref ref-type="bibr" rid="bibr18-0333102412475234">18</xref>), but more studies found that vasodilation outlasted the headache (<xref ref-type="bibr" rid="bibr18-0333102412475234">18</xref>,<xref ref-type="bibr" rid="bibr19-0333102412475234">19</xref>). A post-hoc analysis of a series of human experiments found no linear relationship between experimental immediate headache and dilatation of the intra- and extracerebral arteries (<xref ref-type="bibr" rid="bibr20-0333102412475234">20</xref>). In contrast to the indirect measurement of the vessels (<xref ref-type="bibr" rid="bibr18-0333102412475234">18</xref>,<xref ref-type="bibr" rid="bibr19-0333102412475234">19</xref>), magnetic resonance angiography (MRA) is a noninvasive and widely available technique used to visualize the intracerebral vessels directly. In a randomized, double-blind, crossover study of GTN infusion in healthy volunteers, 1.5T MRA showed a peak vasodilation of the MCA 10–15 minutes (min) after beginning the infusion and a normalization of the vascular diameters to baseline 60 min after starting the infusion (<xref ref-type="bibr" rid="bibr21-0333102412475234">21</xref>). Collectively, these data speak against vasodilation per se as the primary source of pain in GTN-induced immediate headache.</p>
<p>Given the reliable and robust migraine-inducing effects of GTN, the antimigraine action of nonselective nitric oxide synthase (NOS) inhibitor, N(G)-mono-methyl-L-arginine (L-NMMA) was examined, and it was demonstrated that NOS inhibition was effective in treating spontaneous migraine attacks (<xref ref-type="bibr" rid="bibr22-0333102412475234">22</xref>).</p>
<p>The human GTN model can also be used to test prophylactic anti-migraine drugs. Tvedskov and colleagues examined the effect of the prophylactic drug valproate (<xref ref-type="bibr" rid="bibr23-0333102412475234">23</xref>). This study showed that pretreatment with valproat was better than placebo in preventing GTN-induced migraine.</p>
</sec>
<sec id="sec4-0333102412475234"><title>Pitfalls</title>
<p>A number of observations have highlighted the limitations of the GTN model. Thus, despite the robust headache-inducing effects of GTN (<xref ref-type="bibr" rid="bibr6-0333102412475234">6</xref>), a number of subjects do not report migraine attacks. This variation in GTN sensitivity is likely to reflect patient heterogeneity, which also results in differences in sensitivity to other migraine trigger factors (<xref ref-type="bibr" rid="bibr24-0333102412475234">24</xref>,<xref ref-type="bibr" rid="bibr25-0333102412475234">25</xref>). Furthermore, in a 3Tesla MRA study in migraineurs, no statistical significant vasodilation of cerebral or meningeal arteries was reported during GTN-provoked delayed migraine attacks in MO patients (<xref ref-type="bibr" rid="bibr26-0333102412475234">26**</xref>). The lack of GTN-induced vasodilation is in conflict with Doppler studies demonstrating a slight but significant dilatation of MCA (<xref ref-type="bibr" rid="bibr27-0333102412475234">27</xref>,<xref ref-type="bibr" rid="bibr28-0333102412475234">28</xref>) during spontaneous migraine attacks. The discrepancy could be explained either by methodological issues in the MRA studies (<xref ref-type="bibr" rid="bibr26-0333102412475234">26**</xref>,<xref ref-type="bibr" rid="bibr29-0333102412475234">29**</xref>) or possible differences between GTN-induced and spontaneous migraine.</p>
<p>Based on the promising treatment result of nonselective NOS inhibitors (<xref ref-type="bibr" rid="bibr22-0333102412475234">22</xref>), selective inhibition of one of the three NOS isoforms – endothelial (eNOS), neuronal (nNOS), and inducible (iNOS) – seemed to be an attractive approach for the targeted treatment of migraine. The highly selective iNOS inhibitor GW274150 was tested both for acute (<xref ref-type="bibr" rid="bibr30-0333102412475234">30</xref>) and prophylactic (<xref ref-type="bibr" rid="bibr31-0333102412475234">31</xref>) migraine treatment. Surprisingly, and despite high selectivity and potency, GW274150 was not effective, suggesting that iNOS is unlikely to be a promising drug target. GTN infusion (and possibly migraine attacks) may induce the expression of nNOS (<xref ref-type="bibr" rid="bibr32-0333102412475234">32</xref>), and selective nNOS inhibitors show promising results in preclinical pain trials (<xref ref-type="bibr" rid="bibr33-0333102412475234">33</xref>). For now, NOS inhibitors still have to prove their usefulness in migraine treatment.</p>
<p>The GTN models have been used to test acute and preventive drugs. The effect of the specific antimigraine drug sumatriptan, a 5-HT<sub>1B/1D</sub> receptor agonist, on GTN-induced headache has been examined in several studies (<xref ref-type="bibr" rid="bibr34-0333102412475234">34</xref>). In a double-blind crossover study in 10 healthy subjects, 6 mg subcutaneous sumatriptan followed by GTN infusion reduced GTN-induced immediate headache and the temporal and radial artery diameter compared to placebo (<xref ref-type="bibr" rid="bibr35-0333102412475234">35</xref>). Another study by Schmetterer et al. (<xref ref-type="bibr" rid="bibr36-0333102412475234">36</xref>) in healthy subjects confirmed the efficacy of sumatriptan in GTN-induced headache and in addition demonstrated that sumatriptan also prevents GTN-induced dilation of the MCA. When aspirin and zolmitriptan were administered to healthy volunteers after GTN infusion, both drugs had no effect on continuing headache caused by a long-lasting infusion of a relatively low dose of GTN (<xref ref-type="bibr" rid="bibr37-0333102412475234">37</xref>). This suggests that the active drug must then be given as pretreatment before GTN is administered and highlights the need to test treatment in the relevant target population. Tvedskov and colleagues (<xref ref-type="bibr" rid="bibr38-0333102412475234">38</xref>) observed no clinical effect of propranolol on GTN-induced headache and migraine. These data suggested that the efficacy of future prophylactic drugs in the GTN model depends on their mechanism of action. There may also be a different mechanism involved in different patients, so new drugs may not be effective in all patients or all attacks depending on the causative mechanism. Another seemingly negative drug-screening result of the GTN model was the finding that calcitonin gene-related peptide (CGRP) receptor antagonists, which are proven effective in migraine treatment (see below), had no effect on GTN-induced vasodilation in healthy humans (<xref ref-type="bibr" rid="bibr39-0333102412475234">39</xref>) and importantly, did not prevent GTN-induced migraine (<xref ref-type="bibr" rid="bibr40-0333102412475234">40</xref>). This suggests that the migraine-inducing effect of GTN is not caused by CGRP liberation. In summary, the ineffectiveness of a well-proven propranolol and CGRP antagonism efficacy limits the usefulness of the model, and must be considered in future testing of new migraine prophylactic and acute drugs (<xref ref-type="bibr" rid="bibr41-0333102412475234">41</xref>).</p>
</sec>
</sec>
<sec id="sec5-0333102412475234"><title>Future perspectives: Pearls and pitfalls</title>
<p>The results of drug testing in the human model of migraine show major advantages as well as limitations of the GTN model. It is a definitive advantage that a potential prophylactic migraine agent can be tested at a very early stage of development with approximately two weeks’ toxicology. Furthermore, the model allows extensive testing of safety parameters such blood pressure, heart rate and effects of drugs on the cerebral circulation (<xref ref-type="bibr" rid="bibr41-0333102412475234">41</xref>). GTN studies have also shown that the sensitivity of models could be improved with some changes in experimental design. Thus, previous studies underscore the need for well-powered studies to avoid possible type-II errors (<xref ref-type="bibr" rid="bibr23-0333102412475234">23</xref>). Furthermore, the clinical difference could be increased by adapting less conservative migraine criteria, such as probable or migraine-like headache rather than the strict International Headache Society (IHS) criteria (<xref ref-type="bibr" rid="bibr5-0333102412475234">5</xref>); see <xref ref-type="table" rid="table3-0333102412475234">Table 2</xref>.
<table-wrap id="table3-0333102412475234" position="float"><label>Table 2.</label><caption><p>The modified migraine criteria for migraine-like attack in experimental studies.</p></caption>
<graphic alternate-form-of="table3-0333102412475234" xlink:href="10.1177_0333102412475234-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Diagnose</th>
<th>Migraine-like attack after pharmacological provocation</th>
</tr></thead>
<tbody align="left">
<tr>
<td rowspan="10"><bold>Diagnostic criteria</bold></td>
<td><bold>Headache fulfilling either 1 or 2:</bold></td>
</tr>
<tr>
<td><bold>1</bold>: Headache fulfilling ICHD-II criteria C and D for migraine without aura</td>
</tr>
<tr>
<td><bold>C</bold>: Headache has at least two of the following characteristics:</td>
</tr>
<tr>
<td>1) Unilateral location</td>
</tr>
<tr>
<td>2) Pulsating quality</td>
</tr>
<tr>
<td>3) Moderate or severe pain intensity (&gt;4 on VRS)</td>
</tr>
<tr>
<td>4) Aggravation by cough (in-hospital phase) or causing avoidance of routine physical activity (out-hospital phase) (e.g. walking or climbing stairs)</td>
</tr>
<tr>
<td><bold>D</bold>: During headache at least one of the following:</td>
</tr>
<tr>
<td>1) Nausea and/or vomiting</td>
</tr>
<tr>
<td>2) Photophobia and phonophobia</td>
</tr>
<tr>
<td><bold>2:</bold> Headache described as mimicking usual migraine attack and treated with a triptan</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0333102412475234"><p>ICHD-II: Second edition, International Classification of Headache Disorders; VRS: verbal rating scale.</p></fn></table-wrap-foot>
</table-wrap>
</p>
<p>One of the limitations of the model is that a negative result does not prove that the drug does not work in spontaneous migraine (<xref ref-type="bibr" rid="bibr37-0333102412475234">37</xref>). Thus, spontaneous migraine may be induced via a number of different mechanisms, whereas GTN induces migraine via one particular pathway (NO – cGMP) (<xref ref-type="bibr" rid="bibr42-0333102412475234">42</xref>). Efficacy in the model would, on the other hand, imply a high likelihood of clinical efficacy. The GTN model in healthy volunteers is thus a good screening model that allows selection of compounds that should ultimately be tested in patients. Future studies may reveal whether other prophylactic migraine drugs work in the GTN model, whether the model can be used for dose finding in prophylactic studies and how such a dose finding study should best be designed.</p>
</sec>
<sec id="sec6-0333102412475234"><title>Histamine model</title>
<p>Pickering and Hess (<xref ref-type="bibr" rid="bibr43-0333102412475234">43</xref>) reported the first detailed study of the histamine-induced headache. These findings were confirmed in further studies (<xref ref-type="bibr" rid="bibr44-0333102412475234">44</xref><xref ref-type="bibr" rid="bibr45-0333102412475234"/>–<xref ref-type="bibr" rid="bibr46-0333102412475234">46</xref>). It was later established that histamine, in a dose-dependent fashion, caused a more severe and more pulsating headache in migraine patients than in healthy subjects (<xref ref-type="bibr" rid="bibr47-0333102412475234">47</xref>). In a double-blind study, MO patients were randomized to receive either mepyramine (an H1 receptor blocker) or placebo before histamine infusion. Patients who received both histamine and pretreatment with placebo developed a headache peak during infusion (immediate headache), a reduction in headache intensity for approximately two hours (intermediate phase) and a second headache peak several hours later (delayed headache). Seventy percent of patients experienced a migraine-like attack fulfilling the diagnostic criteria for MO (<xref ref-type="bibr" rid="bibr48-0333102412475234">48</xref>). Interestingly, the time profile of the histamine-induced headache in patients is strikingly similar to the time profile of GTN-induced headache in MO patients (<xref ref-type="bibr" rid="bibr6-0333102412475234">6</xref>) (<xref ref-type="fig" rid="fig2-0333102412475234">Figure 2</xref>). Given that activation of endothelial H1-receptors induces the endogenous formation of NO, it is possible that histamine-induced migraine is caused by hypersensitivity to activation of the NO pathway.</p>
<p>The pitfall of histamine models is that an NOS inhibitor in the highest possible dose did not block the histamine-induced headache response or arterial dilatation (<xref ref-type="bibr" rid="bibr49-0333102412475234">49</xref>). This suggests that histamine dilates arteries and causes headache via NO independent mechanisms. Based on these results, antihistamines should have a migraine-relieving effect, possibly by blocking mast cell degranulation (<xref ref-type="bibr" rid="bibr50-0333102412475234">50</xref>).</p>
<p>Few high-quality clinical trials have examined the efficacy of antihistamines as single agents (51), but one small (sub)study examining hydroxyzine in patients with acute MO found no difference compared to placebo (<xref ref-type="bibr" rid="bibr52-0333102412475234">52</xref>), and the prophylactic treatment effect of histamine blockers did not differ from placebo (<xref ref-type="bibr" rid="bibr53-0333102412475234">53</xref>).</p>
</sec>
<sec id="sec7-0333102412475234"><title>CGRP model</title>
<p>CGRP is present in the trigeminal ganglion and in nerve fibers around cerebral (<xref ref-type="bibr" rid="bibr54-0333102412475234">54</xref>) and temporal arteries (<xref ref-type="bibr" rid="bibr55-0333102412475234">55</xref>). In 1988 Goadsby et al. (<xref ref-type="bibr" rid="bibr56-0333102412475234">56</xref>) reported that CGRP was increased in the extracerebral circulation of humans upon thermo coagulation of the trigeminal ganglion. Studies in migraine patients showed elevation of CGRP during (<xref ref-type="bibr" rid="bibr57-0333102412475234">57</xref>) and outside of migraine attacks (<xref ref-type="bibr" rid="bibr58-0333102412475234">58</xref>). However, Tvedskov et al. found no changes in plasma CGRP during migraine attacks compared to outside of attacks (<xref ref-type="bibr" rid="bibr59-0333102412475234">59</xref>) and thus challenged earlier reports.</p>
<p>The importance of CGRP in migraine pathogenesis became firmly established using the experimental migraine model. Lassen et al. (<xref ref-type="bibr" rid="bibr60-0333102412475234">60</xref>) conducted a double-blind cross-over study, where human α-CGRP (2 µg/min) or placebo was infused for 20 min in 12 MO patients. During the following 11 h all patients experienced headaches after human α-CGRP and only one patient after placebo, and in three patients the delayed headache fulfilled the IHS criteria for MO (<xref ref-type="bibr" rid="bibr60-0333102412475234">60</xref>). Applying the criteria presented in <xref ref-type="table" rid="table3-0333102412475234">Table 2</xref>, CGRP-induced migraine-like attacks in 75% of MO patients with (<xref ref-type="bibr" rid="bibr29-0333102412475234">29</xref>) and 57% of patients with migraine with aura (MA) (<xref ref-type="bibr" rid="bibr61-0333102412475234">61</xref>); see <xref ref-type="table" rid="table1-0333102412475234">Table 1(a)</xref>. Ultrasonography studies have shown that CGRP infusion and CGRP-induced headache and migraine were associated with just a modest immediate vasodilation (<xref ref-type="bibr" rid="bibr62-0333102412475234">62</xref>,<xref ref-type="bibr" rid="bibr63-0333102412475234">63</xref>); see <xref ref-type="table" rid="table4-0333102412475234">Table 3</xref>. Hypersensitivity to CGRP infusion in migraineurs triggered interest in CGRP antagonism as a potential target for antimigraine drugs. Indeed, olcegepant, (BIBN 4096), a selective IV-administered CGRP antagonist, was effective in treating acute migraine attacks (<xref ref-type="bibr" rid="bibr65-0333102412475234">65</xref>). The oral CGRP receptor antagonist telcagepant was also effective (<xref ref-type="bibr" rid="bibr65-0333102412475234">65</xref>,<xref ref-type="bibr" rid="bibr66-0333102412475234">66</xref>). Development of this drug was halted in phase III, but new formulations of oral CGRP receptor antagonists are currently in development (<xref ref-type="bibr" rid="bibr67-0333102412475234">67</xref>).
<table-wrap id="table4-0333102412475234" position="float"><label>Table 3.</label><caption><p>Cerebral vascular changes after pharmacological provocation.</p></caption>
<graphic alternate-form-of="table4-0333102412475234" xlink:href="10.1177_0333102412475234-table4.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Compound</th>
<th>Dose</th>
<th>Imaging modality</th>
<th>Middle cerebral artery</th>
<th>Middle meningeal artery</th>
<th>Superficial temporal artery</th>
<th>Basilar artery</th>
<th>Ref.</th>
</tr></thead>
<tbody align="left">
<tr>
<td>GTN</td>
<td>Intravenous 0.5 µg/kg/min</td>
<td>MRA, TCD and Dermascan</td>
<td>+11.7%–25% (infusion) + 4% (migraine)</td>
<td>+16.4% (infusion) −1.78% (migraine)</td>
<td>+ 35%</td>
<td>+20.7% infusion</td>
<td>(<xref ref-type="bibr" rid="bibr21-0333102412475234">21</xref>,<xref ref-type="bibr" rid="bibr26-0333102412475234">26**</xref>,<xref ref-type="bibr" rid="bibr38-0333102412475234">38</xref>)</td>
</tr>
<tr>
<td>Histamine</td>
<td>Intravenous 0.5 µg/kg/min</td>
<td>TCD and Dermascan</td>
<td>−26.0 ± 2.3% (mean blood flow velocity)</td>
<td>N/D</td>
<td>+58.7%</td>
<td>N/D</td>
<td>(<xref ref-type="bibr" rid="bibr49-0333102412475234">49</xref>)</td>
</tr>
<tr>
<td>Sildenafil</td>
<td>100 mg per os</td>
<td>TCD and Dermascan</td>
<td>No change</td>
<td>N/D</td>
<td>No change</td>
<td>N/D</td>
<td>(<xref ref-type="bibr" rid="bibr71-0333102412475234">71**</xref>)</td>
</tr>
<tr>
<td>Dipyridamole</td>
<td>Intravenous 0.142 mg/kg/min</td>
<td>TCD</td>
<td>−16.3% (mean blood flow velocity) + 5.6% (diameter change)</td>
<td>N/D</td>
<td>N/D</td>
<td>N/D</td>
<td>(<xref ref-type="bibr" rid="bibr73-0333102412475234">73</xref>,<xref ref-type="bibr" rid="bibr125-0333102412475234">125</xref>)</td>
</tr>
<tr>
<td>CGRP</td>
<td>Intravenous 1.5–2 µg/min</td>
<td>MRA, TCD and Dermascan</td>
<td>+7.5%–9.3% (TCD) 11.22% (MRA)</td>
<td>+9.24% (MRA)</td>
<td>+42.8% (Dermascan)</td>
<td>N/D</td>
<td>(<xref ref-type="bibr" rid="bibr29-0333102412475234">29**</xref>,<xref ref-type="bibr" rid="bibr62-0333102412475234">62</xref>,<xref ref-type="bibr" rid="bibr63-0333102412475234">63</xref>,<xref ref-type="bibr" rid="bibr116-0333102412475234">116**</xref>)</td>
</tr>
<tr>
<td>VIP</td>
<td>Intravenous 8 pmol/kg/min</td>
<td>TCD and Dermascan</td>
<td>−16.3% (mean blood flow velocity)</td>
<td>N/D</td>
<td>+45.9 %</td>
<td>N/D</td>
<td>(<xref ref-type="bibr" rid="bibr83-0333102412475234">83</xref>)</td>
</tr>
<tr>
<td>PACAP-38</td>
<td>Intravenous 10 pmol/ kg/min</td>
<td>MRA, TCD and Dermascan</td>
<td>No change (MRA) 6%–9.5% (TCD)</td>
<td>+23.4% (MRA)</td>
<td>+50%</td>
<td>N/D</td>
<td>(<xref ref-type="bibr" rid="bibr85-0333102412475234">85**</xref>,<xref ref-type="bibr" rid="bibr86-0333102412475234">86</xref>,<xref ref-type="bibr" rid="bibr126-0333102412475234">126</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0333102412475234"><p>GTN: glyceryl trinitrate; MRA: magnetic resonance angiography; TCD: transcranial Doppler; Dermascan: ultrasound; N/D: not determined; CGRP: calcitonin gene-related peptide; VIP: vasoactive intestinal peptide; PACAP-38: pituitary adenylate cyclase-activating polypeptide-38.</p></fn></table-wrap-foot>
</table-wrap>
</p>
<p>The vascular effects of CGRP infusion in healthy volunteers was investigated with high-resolution 3T MRI. This study showed that CGRP caused significant dilation of the extracerebral middle meningeal artery (MMA) but not of the intracerebral MCA compared with placebo (<xref ref-type="bibr" rid="bibr68-0333102412475234">68</xref>). Interestingly, the headache-aborting effect of sumatriptan was associated with constriction of the MMA but not MCA. Furthermore, in contrast to GTN-induced migraine (<xref ref-type="bibr" rid="bibr26-0333102412475234">26**</xref>), CGRP-induced MO was associated with dilation of extra- and intracerebral arteries, and headache location corresponded to the location of vasodilation (<xref ref-type="bibr" rid="bibr29-0333102412475234">29**</xref>). This suggests that vasodilation and perivascular release of vasoactive substances are an integral part of migraine pathophysiology.</p>
</sec>
<sec id="sec8-0333102412475234"><title>Phosphodiesterase (PDE) inhibitor model</title>
<p>Several substances capable of inducing experimental vascular headache do so via NO or molecules in the cascade of intracellular reactions triggered by NO (<xref ref-type="bibr" rid="bibr69-0333102412475234">69</xref>) and activating the NO-cyclic GMP pathway (<xref ref-type="bibr" rid="bibr42-0333102412475234">42</xref>). A good example is sildenafil (Viagra™), a selective inhibitor of cGMP-hydrolyzing PDE5. Inhibition of this enzyme results in accumulation of cGMP, and the effect of sildenafil could therefore mimic the effects of NO, which increases cGMP formation via activation of soluble guanylate cyclase. When given to healthy volunteers in the human model, sildenafil caused significantly more headache than placebo, interestingly without cerebral arterial dilation (<xref ref-type="bibr" rid="bibr70-0333102412475234">70</xref>). To verify this in migraine patients, 12 MO patients were included in a double-blind, placebo-controlled crossover study in which placebo or sildenafil 100 mg was administered orally on two separate days (<xref ref-type="bibr" rid="bibr71-0333102412475234">71**</xref>). Sildenafil induced a migraine-like attack in 10 of 12 patients compared with a placebo response in two of 12 patients. The authors also found that blood flow velocity in the MCA, regional cerebral blood flow in the territory of the MCA and the diameter of the radial and temporal arteries were unaffected by sildenafil (<xref ref-type="bibr" rid="bibr71-0333102412475234">71**</xref>). Thus, it appears that sildenafil triggered experimental migraine via a cGMP-dependent mechanism but without initial dilation of the MCA. The authors proposed that triggering mechanisms might reside within the perivascular sensory nerve terminals or the brainstem (<xref ref-type="bibr" rid="bibr71-0333102412475234">71**</xref>). However, future studies are needed to explore the molecular sites of action responsible for sildenafil-induced experimental migraine, including MRA of the dural arteries. A functional magnetic resonance imaging (fMRI) study excluded that the headache-inducing properties of sildenafil were related to a general lowering of threshold for a neuronal or cerebrovascular response, at least in healthy volunteers (<xref ref-type="bibr" rid="bibr72-0333102412475234">72</xref>).</p>
<p>Other PDE inhibitors have also been studied in humans. The migraine- and headache-eliciting effect of the PDE5 inhibitor dipyridamole was examined in a single-blind study, including 10 migraineurs and 10 healthy controls (<xref ref-type="bibr" rid="bibr73-0333102412475234">73</xref>). Dipyridamole induced headache in all patients and migraine attack in 50% of patients (<xref ref-type="table" rid="table1-0333102412475234">Table 1(a)</xref> and (<xref ref-type="table" rid="table2-0333102412475234">b</xref>)). The headache-generating effect of cilostazol, an inhibitor of cAMP-degrading PDE3, has been studied in healthy subjects (<xref ref-type="bibr" rid="bibr74-0333102412475234">74</xref>). The participants received either cilostazol 200 mg or placebo. The authors reported that cilostazol induced moderate headache in 11 of 12 participants with no family history of migraine. The headache in most cases had migraine-like features such as pulsating pain quality and aggravation by physical activity. In two participants, the symptoms fulfilled criteria for an attack of MO. Interestingly, cilostazol is one of the most important cAMP-degrading enzymes in cerebral arteries, and it has been suggested that not only cGMP but also cAMP-dependent pathways may be involved in the pathogenesis of head pain (<xref ref-type="bibr" rid="bibr74-0333102412475234">74</xref>). The effect of cilostazol in migraine patients should be examined in future studies. The headache-eliciting effects of PDEs have not been tested in MA patients. In a case report, tadalafil was associated with visual aura symptoms (<xref ref-type="bibr" rid="bibr75-0333102412475234">75</xref>).
</p>
</sec>
<sec id="sec9-0333102412475234"><title>Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) models</title>
<p>VIP and PACAP are found in perivascular parasympathetic nerve fibers (<xref ref-type="bibr" rid="bibr76-0333102412475234">76</xref>), and PACAP is also found in trigeminal nerve fibers surrounding cerebral blood vessels (<xref ref-type="bibr" rid="bibr77-0333102412475234">77</xref>). Their release regulates cerebrovascular tone and hemodynamics of the brain (<xref ref-type="bibr" rid="bibr78-0333102412475234">78</xref>). Two receptors, VPAC<sub>1</sub> (<xref ref-type="bibr" rid="bibr79-0333102412475234">79</xref>) and VPAC<sub>2</sub> (<xref ref-type="bibr" rid="bibr80-0333102412475234">80</xref>), are activated with equal affinity by PACAP and VIP, but a third receptor, PAC<sub>1,</sub> is selectively activated by PACAP (<xref ref-type="bibr" rid="bibr81-0333102412475234">81</xref>).</p>
<p>The systemic administration of VIP induces only a short-lasting and mild headache in healthy controls (<xref ref-type="bibr" rid="bibr82-0333102412475234">82</xref>) and a very mild and short-lasting headache, and no migraine attacks in MO patients (<xref ref-type="bibr" rid="bibr83-0333102412475234">83</xref>). VIP does not seem to be a trigger factor for headache and migraine, and VIP is probably not critically involved in migraine pathogenesis (<xref ref-type="bibr" rid="bibr84-0333102412475234">84</xref>).</p>
<p>Interestingly, PACAP38 infusion led to sustained dilation of the superficial temporal artery (STA), and in contrast to VIP, PACAP induces more headache and often migraine-like attacks in MO patients (<xref ref-type="bibr" rid="bibr85-0333102412475234">85**</xref>). In healthy volunteers, high-resolution MRA showed that PACAP38-induced headache was associated with prolonged dilation of the MMA but not of the MCA (<xref ref-type="bibr" rid="bibr86-0333102412475234">86</xref>).</p>
<p>Given that VIP infusion does not cause migraine, the shared VIP/PACAP receptors are unlikely to be causal for induction of migraine after PACAP-38 infusion. The migraine induction by PACAP-38, in contrast to VIP, might be due to the selective action of PACAP38 on the PAC<sub>1</sub> receptor (<xref ref-type="bibr" rid="bibr87-0333102412475234">87</xref>). Further studies are warranted to investigate the pronociceptive mechanisms of PACAP that could involve central sensitization (<xref ref-type="bibr" rid="bibr88-0333102412475234">88</xref>) or mast cell degranulation (<xref ref-type="bibr" rid="bibr89-0333102412475234">89</xref>), which include secretion of histamine, serotonin, prostanoids and cytokines (<xref ref-type="bibr" rid="bibr90-0333102412475234">90</xref>).</p>
</sec>
<sec id="sec10-0333102412475234"><title>Prostaglandin model</title>
<p>Over the past years we have systematically investigated the role of prostaglandins (PGs) in the generation of headache in healthy volunteers and migraine sufferers. The intravenous administration of vasodilating PGs, such as PGI<sub>2</sub> (prostacyclin), PGE<sub>2</sub> and PGD<sub>2</sub>, induced headache in healthy volunteers and PGI<sub>2</sub> triggered migraine-like attacks in migraine patients (<xref ref-type="bibr" rid="bibr91-0333102412475234">91</xref><xref ref-type="bibr" rid="bibr92-0333102412475234"/><xref ref-type="bibr" rid="bibr93-0333102412475234"/>–<xref ref-type="bibr" rid="bibr94-0333102412475234">94</xref>). Interestingly, the infusion of PGE<sub>2</sub> caused immediate migraine-like attacks accompanied by vasodilation of the MCA and insignificant vasodilation of the STA in MO patients (<xref ref-type="bibr" rid="bibr95-0333102412475234">95**</xref>). The fact that PGE<sub>2</sub> selectively triggers immediate migraine-like attacks is at odds with all other tested migraine-inducing substances; see <xref ref-type="table" rid="table5-0333102412475234">Table 4</xref>. MRI verification of dilation of cerebral or extracerebral arteries in PG-induced headache or migraine is pending. Given that PGs are inflammatory mediators (<xref ref-type="bibr" rid="bibr96-0333102412475234">96</xref>) capable of activating sensory afferents, it could be speculated that PG-induced vasodilation does not contribute to provoked headache. To investigate the role of inflammation and vasodilation in PG-induced headache, we investigated whether the pro-inflammatory and vasoconstricting prostanoid prostaglandin F<sub>2α</sub> (PGF<sub>2α</sub>) would cause headache in a human model of headache. PGF<sub>2α</sub>, as opposed to PGE<sub>2</sub>, PGI<sub>2</sub> and PGD<sub>2</sub>, did not induce headache (<xref ref-type="bibr" rid="bibr97-0333102412475234">97</xref>). The lack of a dilating effect of PGF<sub>2α</sub> on cerebral arteries could explain the absence of headache. Based on these data we suggest that the vasodilating abilities of PGs are important in generating pain in healthy volunteers and are likely to play a role in the mechanisms of spontaneous migraine attacks.
<table-wrap id="table5-0333102412475234" position="float"><label>Table 4.</label><caption><p>Percentage of migraine patients reporting immediate and delayed migraine-like attacks after pharmacological provocation.</p></caption>
<graphic alternate-form-of="table5-0333102412475234" xlink:href="10.1177_0333102412475234-table5.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Compound</th>
<th>Immediate migraine-like attacks</th>
<th>Delayed migraine-like attacks</th>
</tr></thead>
<tbody align="left">
<tr>
<td>GTN (6)</td>
<td>10% (1/10)</td>
<td>80% (8/10)</td>
</tr>
<tr>
<td>PACAP-38 (86**)</td>
<td>9% (1/11)</td>
<td>55% (6/11)</td>
</tr>
<tr>
<td>PGI2 (93)</td>
<td>25% (3/12)</td>
<td>50% (6/12)</td>
</tr>
<tr>
<td>CGRP (62)</td>
<td>0% (0/9)</td>
<td>56% (6/9)</td>
</tr>
<tr>
<td>PGE2 (95**)</td>
<td>58% (7/12)</td>
<td>17% (2/12)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0333102412475234"><p>GTN: glyceryl trinitrate; PACAP-38: pituitary adenylate cyclase-activating polypeptide; PGI2: prostaglandin I2; CGRP: calcitonin gene-related peptide; PGE2: prostaglandin E2.</p></fn></table-wrap-foot>
</table-wrap></p>
<sec id="sec11-0333102412475234"><title>Pitfalls</title>
<p>The PGE<sub>2</sub> model of headache in drug testing was recently studied in healthy volunteers. A highly specific and potent EP<sub>4</sub> receptor antagonist, BGC20-1531, was not able to attenuate PGE<sub>2</sub>-induced headache and vasodilation of intra- or extracerebral arteries (<xref ref-type="bibr" rid="bibr98-0333102412475234">98</xref>). The missing attenuation of headache and vasodilation by BGC20-1531 suggests either that the EP<sub>4</sub> receptor is not involved or that a single receptor blockade may not be enough. It should be emphasized that a lack of efficacy of EP<sub>4</sub> receptor antagonist in the PGE<sub>2</sub> model in healthy volunteers does not exclude the possible efficacy of EP<sub>4</sub> antagonist as an acute or preventive drug in migraine.</p>
</sec>
</sec>
<sec id="sec12-0333102412475234"><title>The use of human models to explore migraine aura</title>
<p>Migraine aura is likely to be the symptom of cortical spreading depression (CSD) (<xref ref-type="bibr" rid="bibr99-0333102412475234">99</xref>) originally described by Leão (<xref ref-type="bibr" rid="bibr100-0333102412475234">100</xref>). In rats, CSD leads to activation of nociceptors that innervate the meninges (<xref ref-type="bibr" rid="bibr101-0333102412475234">101</xref>) and it also activates central trigeminovascular neurons (<xref ref-type="bibr" rid="bibr102-0333102412475234">102</xref>), thereby linking CSD to delayed activation of the trigeminovascular pathway and potentially to the development of headache (<xref ref-type="bibr" rid="bibr103-0333102412475234">103</xref>).</p>
<p>Attempts have been made to trigger aura in migraineurs using human models of migraine. Afridi et al. (<xref ref-type="bibr" rid="bibr104-0333102412475234">104</xref>) reported that one out of 21 MA patients had an aura triggered on two separate occasions by GTN, and one during the second session only. Following sublingual GTN provocation, Sances et al. (<xref ref-type="bibr" rid="bibr7-0333102412475234">7</xref>) reported that three of 22 (14%) developed a visual aura. Interestingly, CGRP infusion in 14 MA patients resulted in visual aura in four of 14 (29%) (<xref ref-type="bibr" rid="bibr61-0333102412475234">61</xref>). However, given that relatively few MA patients experience aura during provocation studies with GTN and CGRP, these findings may be due to random occurrence of MA, and other methods of aura induction are needed. Using GTN, Christiansen et al. (<xref ref-type="bibr" rid="bibr105-0333102412475234">105</xref>) demonstrated that 50% of the patients suffering exclusively from MA developed migraine headache with associated symptoms, but none developed migraine aura.</p>
<p>Two studies reported aura triggered by visual stimuli and vigorous physical activity in a few MA patients (<xref ref-type="bibr" rid="bibr106-0333102412475234">106</xref>,<xref ref-type="bibr" rid="bibr107-0333102412475234">107</xref>). Not all migraine patients, however, seem susceptible to these triggers (<xref ref-type="bibr" rid="bibr25-0333102412475234">25</xref>). In patients undergoing conventional digital subtraction angiography (DSA), aura symptoms and possibly CSD were triggered shortly after the angiographic procedure (<xref ref-type="bibr" rid="bibr99-0333102412475234">99</xref>). Animal studies have provided a number of possible CSD triggers (<xref ref-type="bibr" rid="bibr108-0333102412475234">108</xref>,<xref ref-type="bibr" rid="bibr109-0333102412475234">109</xref>) that eventually could be modified and tested in humans. We still need a reproducible and reliable experimental model to induce aura episodes in MA patients.</p>
</sec>
<sec id="sec13-0333102412475234"><title>The use of human models to explore the contribution of genetic susceptibility</title>
<p>Familial hemiplegic migraine (FHM) is a rare, dominantly inherited subtype of MA in which hemiplegia occurs during the aura phase (<xref ref-type="bibr" rid="bibr5-0333102412475234">5</xref>). The identification of FHM genes (<xref ref-type="bibr" rid="bibr110-0333102412475234">110</xref><xref ref-type="bibr" rid="bibr111-0333102412475234"/>–<xref ref-type="bibr" rid="bibr112-0333102412475234">112</xref>) stimulated interest in the link between genotype and phenotype using molecular studies and animal models. Thus, FHM knock-in mice show increased susceptibility to CSD (<xref ref-type="bibr" rid="bibr113-0333102412475234">113</xref>,<xref ref-type="bibr" rid="bibr114-0333102412475234">114</xref>). The functional consequences of the FHM mutations in humans, however, are unknown, and the potential species differences should be considered. Genotyped FHM patients offer us the chance to study the interplay between genotype and phenotype and may be regarded as a valuable genetic migraine model (<xref ref-type="bibr" rid="bibr115-0333102412475234">115</xref>). We therefore examined the relationship between the FHM phenotype, including patients with and without FHM mutations and the known migraine-inducing substances GTN and CGRP. To our surprise, both GTN (<xref ref-type="bibr" rid="bibr122-0333102412475234">122</xref>,<xref ref-type="bibr" rid="bibr123-0333102412475234">123</xref>) and CGRP (<xref ref-type="bibr" rid="bibr116-0333102412475234">116**</xref>,<xref ref-type="bibr" rid="bibr117-0333102412475234">117</xref>) failed to induce more migraine headache in FHM patients than in healthy controls, and neither induced aura in FHM patients. Our data indicate that the FHM genotype does not confer hypersensitivity to migraine triggers such as GTN and CGRP. We did, however, observe that the few FHM patients reporting migraine-like attacks after pharmacological provocation tended to be those who also had attacks of MA or MO. It might be important to distinguish between patients with the pure FHM phenotype and FHM patients with co-existing migraine. We therefore examined FHM with and without typical migraines. Our experiments showed that FHM patients with co-existing MA/MO attacks were more sensitive to GTN than patients with the pure FHM phenotype (<xref ref-type="bibr" rid="bibr118-0333102412475234">118</xref>).</p>
<p>Collectively, these results suggest, but do not prove, that migraine-triggering mechanisms in FHM are distinct from those in MO and typical MA and question whether FHM is part of the spectrum of prevalent migraine disorders. This has implications for our understanding of migraine mechanisms and suggests that caution is warranted when extrapolating results from FHM studies to the prevalent types of migraine.</p>
</sec>
<sec id="sec14-0333102412475234"><title>Open questions and future studies</title>
<p>When planning experiments using the human model, it should be kept in mind that migraine symptoms develop gradually (<xref ref-type="bibr" rid="bibr119-0333102412475234">119</xref>); so that during the early stages of an attack these symptoms may not meet the criteria for definitive diagnosis of migraine (<xref ref-type="bibr" rid="bibr120-0333102412475234">120</xref>). Patients should be asked to refrain from abortive medication until they fulfill the migraine criteria. We have developed criteria for a migraine-like attack in experimental studies (<xref ref-type="table" rid="table3-0333102412475234">Table 2</xref>) and suggest that patient-reported migraine, or probable migraine rather than IHS migraine, should be chosen as the primary migraine-related outcome parameter.</p>
</sec>
<sec id="sec15-0333102412475234" sec-type="conclusions"><title>Conclusion</title>
<p>The use of human models of migraine offer unique possibilities to understand the basic migraine mechanisms, including the very onset of symptoms (<xref ref-type="bibr" rid="bibr13-0333102412475234">13</xref>), the mechanisms of antimigraine drugs (<xref ref-type="bibr" rid="bibr29-0333102412475234">29**</xref>) and the difference between different migraine phenotypes (<xref ref-type="bibr" rid="bibr121-0333102412475234">121</xref>).</p>
<p>Furthermore, the human models have contributed to the identification of new specific targets in the treatment of acute migraine attacks such as GTN and CGRP and the confirmed antimigraine action of antagonists to these migraine-inducing substances. The experimental migraine model is an important part of the translational research effort in migraine-drug development. New additions to the model, such as advanced imaging methods, may lead to a better understanding of the complex events that constitute a migraine attack and to better and more targeted ways of intervention.</p>
</sec>
</body>
<back>
<ack><title>Acknowledgments</title>
<p>We thank all patients and healthy volunteers who participated in the reported studies.</p></ack>
<sec id="sec16-0333102412475234"><title>Funding</title>
<p>Studies included in this review were supported by grants from the University of Copenhagen, the Lundbeck Foundation through the Center for Neurovascular Signaling (LUCENS), The Research Foundation of the Capital Region of Denmark; Danish Council for Independent Research-Medical Sciences (FSS) (grant 271-08-0446); and The Novo Nordisk Foundation (R172-A14333).</p>
</sec>
<sec id="sec17-0333102412475234"><title>Conflict of interest</title>
<p>None declared.</p>
</sec>
<ref-list><title>References</title>
<ref id="bibr1-0333102412475234"><label>1</label><citation citation-type="other"><comment>Hering C. Glonoine, a new medicine for headache etc. <italic>Am J Homeopathy</italic> 1849: 3</comment>.</citation></ref>
<ref id="bibr2-0333102412475234"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tfelt-Hansen</surname><given-names>PC</given-names></name><name><surname>Tfelt-Hansen</surname><given-names>J</given-names></name></person-group>. <article-title>Nitroglycerin headache and nitroglycerin-induced primary headaches from 1846 and onwards: A historical overview and an update</article-title>. <source>Headache</source> <year>2009</year>; <volume>49</volume>: <fpage>445</fpage>–<lpage>456</lpage>.</citation></ref>
<ref id="bibr3-0333102412475234"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iversen</surname><given-names>HK</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Tfelt-Hansen</surname><given-names>P</given-names></name></person-group>. <article-title>Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics</article-title>. <source>Pain</source> <year>1989</year>; <volume>38</volume>: <fpage>17</fpage>–<lpage>24</lpage>.</citation></ref>
<ref id="bibr4-0333102412475234"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Iversen</surname><given-names>HK</given-names></name><name><surname>Thomsen</surname><given-names>LL</given-names></name></person-group>. <article-title>Nitric oxide supersensitivity: A possible molecular mechanism of migraine pain</article-title>. <source>Neuroreport</source> <year>1993</year>; <volume>4</volume>: <fpage>1027</fpage>–<lpage>1030</lpage>. <comment>**<bold>In a double-blind study it was discovered that migraine patients are supersensitive to exogenous nitric oxide from nitroglycerin.</bold></comment>.</citation></ref>
<ref id="bibr5-0333102412475234"><label>5</label><citation citation-type="journal"><collab>Headache Classification Committee</collab>. <article-title>The International Classification of Headache Disorders: 2nd edition</article-title>. <source>Cephalalgia</source> <year>2004</year>; <volume>24</volume>(<supplement>Suppl 1</supplement>): <fpage>9</fpage>–<lpage>160</lpage>.</citation></ref>
<ref id="bibr6-0333102412475234"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thomsen</surname><given-names>LL</given-names></name><name><surname>Kruuse</surname><given-names>C</given-names></name><name><surname>Iversen</surname><given-names>HK</given-names></name><etal/></person-group>. <article-title>A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks</article-title>. <source>Eur J Neurol</source> <year>1994</year>; <volume>1</volume>: <fpage>73</fpage>–<lpage>80</lpage>.</citation></ref>
<ref id="bibr7-0333102412475234"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sances</surname><given-names>G</given-names></name><name><surname>Tassorelli</surname><given-names>C</given-names></name><name><surname>Pucci</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Reliability of the nitroglycerin provocative test in the diagnosis of neurovascular headaches</article-title>. <source>Cephalalgia</source> <year>2004</year>; <volume>24</volume>: <fpage>110</fpage>–<lpage>119</lpage>.</citation></ref>
<ref id="bibr8-0333102412475234"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Afridi</surname><given-names>SK</given-names></name><name><surname>Matharu</surname><given-names>MS</given-names></name><name><surname>Lee</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate</article-title>. <source>Brain</source> <year>2005</year>; <volume>128</volume>: <fpage>932</fpage>–<lpage>939</lpage>.</citation></ref>
<ref id="bibr9-0333102412475234"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bahra</surname><given-names>A</given-names></name><name><surname>Matharu</surname><given-names>MS</given-names></name><name><surname>Buchel</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Brainstem activation specific to migraine headache</article-title>. <source>Lancet</source> <year>2001</year>; <volume>357</volume>: <fpage>1016</fpage>–<lpage>1017</lpage>.</citation></ref>
<ref id="bibr10-0333102412475234"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weiller</surname><given-names>C</given-names></name><name><surname>May</surname><given-names>A</given-names></name><name><surname>Limmroth</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Brain stem activation in spontaneous human migraine attacks</article-title>. <source>Nat Med</source> <year>1995</year>; <volume>1</volume>: <fpage>658</fpage>–<lpage>660</lpage>.</citation></ref>
<ref id="bibr11-0333102412475234"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Afridi</surname><given-names>SK</given-names></name><name><surname>Giffin</surname><given-names>NJ</given-names></name><name><surname>Kaube</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>A positron emission tomographic study in spontaneous migraine</article-title>. <source>Arch Neurol</source> <year>2005</year>; <volume>62</volume>: <fpage>1270</fpage>–<lpage>1275</lpage>. <comment>**<bold>Positron-emission tomographic (PET) study of spontaneous migraine attacks reporting significant activation in the dorsal pons along with activation of other cortical and subcortical structures.</bold></comment>.</citation></ref>
<ref id="bibr12-0333102412475234"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Afridi</surname><given-names>SK</given-names></name><name><surname>Kaube</surname><given-names>H</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name></person-group>. <article-title>Glyceryl trinitrate triggers premonitory symptoms in migraineurs</article-title>. <source>Pain</source> <year>2004</year>; <volume>110</volume>: <fpage>675</fpage>–<lpage>680</lpage>. <comment>**<bold>Study showed that in some patients glyceryl trinitrate (GTN) could induce typical premonitory symptoms, supporting that GTN is not just a trigger of pain, but triggers genuine migraine.</bold></comment>.</citation></ref>
<ref id="bibr13-0333102412475234"><label>13</label><citation citation-type="other"><comment>Sprenger T, Maniyar FH, Monteith TS, et al. Midbrain activation in the premonitory phase of migraine: A H2O-positron emission tomography study. In: <italic>American Headache Society 54th Annual Scientific Meeting,</italic> Los Angeles, CA, USA, 2012; <italic>Headache</italic> 2012; 863–864</comment>.</citation></ref>
<ref id="bibr14-0333102412475234"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giffin</surname><given-names>NJ</given-names></name><name><surname>Ruggiero</surname><given-names>L</given-names></name><name><surname>Lipton</surname><given-names>RB</given-names></name><etal/></person-group>. <article-title>Premonitory symptoms in migraine: An electronic diary study</article-title>. <source>Neurology</source> <year>2003</year>; <volume>60</volume>: <fpage>935</fpage>–<lpage>940</lpage>.</citation></ref>
<ref id="bibr15-0333102412475234"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>FT 3rd</given-names></name><name><surname>Mawad</surname><given-names>M</given-names></name><name><surname>Mohr</surname><given-names>JP</given-names></name><etal/></person-group>. <article-title>Focal headache during balloon inflation in the internal carotid and middle cerebral arteries</article-title>. <source>Stroke</source> <year>1990</year>; <volume>21</volume>: <fpage>555</fpage>–<lpage>559</lpage>.</citation></ref>
<ref id="bibr16-0333102412475234"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thomsen</surname><given-names>LL</given-names></name><name><surname>Iversen</surname><given-names>HK</given-names></name><name><surname>Brinck</surname><given-names>TA</given-names></name><etal/></person-group>. <article-title>Arterial supersensitivity to nitric oxide (nitroglycerin) in migraine sufferers</article-title>. <source>Cephalalgia</source> <year>1993</year>; <volume>13</volume>: <fpage>395</fpage>–<lpage>399</lpage>. <comment>discussion 376</comment>.</citation></ref>
<ref id="bibr17-0333102412475234"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Christiansen</surname><given-names>I</given-names></name><name><surname>Iversen</surname><given-names>HK</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Nitric oxide-induced headache may arise from extracerebral arteries as judged from tolerance to isosorbide-5-mononitrate</article-title>. <source>J Headache Pain</source> <year>2008</year>; <volume>9</volume>: <fpage>215</fpage>–<lpage>220</lpage>.</citation></ref>
<ref id="bibr18-0333102412475234"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tegeler</surname><given-names>CH</given-names></name><name><surname>Davidai</surname><given-names>G</given-names></name><name><surname>Gengo</surname><given-names>FM</given-names></name><etal/></person-group>. <article-title>Middle cerebral artery velocity correlates with nitroglycerin-induced headache onset</article-title>. <source>J Neuroimaging</source> <year>1996</year>; <volume>6</volume>: <fpage>81</fpage>–<lpage>86</lpage>.</citation></ref>
<ref id="bibr19-0333102412475234"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iversen</surname><given-names>HK</given-names></name><name><surname>Holm</surname><given-names>S</given-names></name><name><surname>Friberg</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Intracranial hemodynamics during intravenous infusion of glyceryl trinitrate</article-title>. <source>J Headache Pain</source> <year>2008</year>; <volume>9</volume>: <fpage>177</fpage>–<lpage>180</lpage>.</citation></ref>
<ref id="bibr20-0333102412475234"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ashina</surname><given-names>M</given-names></name><name><surname>Tfelt-Hansen</surname><given-names>P</given-names></name><name><surname>Dalgaard</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Lack of correlation between vasodilatation and pharmacologically induced immediate headache in healthy subjects</article-title>. <source>Cephalalgia</source> <year>2011</year>; <volume>31</volume>: <fpage>683</fpage>–<lpage>690</lpage>.</citation></ref>
<ref id="bibr21-0333102412475234"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>JM</given-names></name><name><surname>Pedersen</surname><given-names>D</given-names></name><name><surname>Larsen</surname><given-names>VA</given-names></name><etal/></person-group>. <article-title>Magnetic resonance angiography shows dilatation of the middle cerebral artery after infusion of glyceryl trinitrate in healthy volunteers</article-title>. <source>Cephalalgia</source> <year>2007</year>; <volume>27</volume>: <fpage>118</fpage>–<lpage>127</lpage>.</citation></ref>
<ref id="bibr22-0333102412475234"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lassen</surname><given-names>LH</given-names></name><name><surname>Ashina</surname><given-names>M</given-names></name><name><surname>Christiansen</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Nitric oxide synthase inhibition in migraine</article-title>. <source>Lancet</source> <year>1997</year>; <volume>349</volume>: <fpage>401</fpage>–<lpage>402</lpage>.</citation></ref>
<ref id="bibr23-0333102412475234"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tvedskov</surname><given-names>JF</given-names></name><name><surname>Thomsen</surname><given-names>LL</given-names></name><name><surname>Iversen</surname><given-names>HK</given-names></name><etal/></person-group>. <article-title>The prophylactic effect of valproate on glyceryltrinitrate induced migraine</article-title>. <source>Cephalalgia</source> <year>2004</year>; <volume>24</volume>: <fpage>576</fpage>–<lpage>585</lpage>.</citation></ref>
<ref id="bibr24-0333102412475234"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>DI</given-names></name><name><surname>De ver Dye</surname><given-names>T</given-names></name></person-group>. <article-title>Migraine and the environment</article-title>. <source>Headache</source> <year>2009</year>; <volume>49</volume>: <fpage>941</fpage>–<lpage>952</lpage>.</citation></ref>
<ref id="bibr25-0333102412475234"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hauge</surname><given-names>A</given-names></name><name><surname>Kirchmann</surname><given-names>M</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name></person-group>. <article-title>Trigger factors in migraine with aura</article-title>. <source>Cephalalgia</source> <year>2010</year>; <volume>30</volume>: <fpage>346</fpage>–<lpage>353</lpage>.</citation></ref>
<ref id="bibr26-0333102412475234"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schoonman</surname><given-names>GG</given-names></name><name><surname>van der Grond</surname><given-names>J</given-names></name><name><surname>Kortmann</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Migraine headache is not associated with cerebral or meningeal vasodilatation – a 3T magnetic resonance angiography study</article-title>. <source>Brain</source> <year>2008</year>; <volume>131</volume>: <fpage>2192</fpage>–<lpage>2200</lpage>. <comment>**<bold>Magnetic resonance angiography (MRA) study reporting that GTN-induced migraine attacks are not associated with vasodilation of cerebral or meningeal blood vessels.</bold></comment>.</citation></ref>
<ref id="bibr27-0333102412475234"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thomsen</surname><given-names>LL</given-names></name><name><surname>Iversen</surname><given-names>HK</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name></person-group>. <article-title>Cerebral blood flow velocities are reduced during attacks of unilateral migraine without aura</article-title>. <source>Cephalalgia</source> <year>1995</year>; <volume>15</volume>: <fpage>109</fpage>–<lpage>116</lpage>.</citation></ref>
<ref id="bibr28-0333102412475234"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friberg</surname><given-names>L</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Iversen</surname><given-names>HK</given-names></name><etal/></person-group>. <article-title>Migraine pain associated with middle cerebral artery dilatation: Reversal by sumatriptan</article-title>. <source>Lancet</source> <year>1991</year>; <volume>338</volume>: <fpage>13</fpage>–<lpage>17</lpage>.</citation></ref>
<ref id="bibr29-0333102412475234"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asghar</surname><given-names>MS</given-names></name><name><surname>Hansen</surname><given-names>AE</given-names></name><name><surname>Amin</surname><given-names>FM</given-names></name><etal/></person-group>. <article-title>Evidence for a vascular factor in migraine</article-title>. <source>Ann Neurol</source> <year>2011</year>; <volume>69</volume>: <fpage>635</fpage>–<lpage>645</lpage>. <comment>**<bold>MRA study reporting that calcitonin gene-related peptide (CGRP)-induced migraine without aura is associated with dilation of extra- and intracerebral arteries and that the headache location is associated with the location of the vasodilation.</bold></comment>.</citation></ref>
<ref id="bibr30-0333102412475234"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van der Schueren</surname><given-names>BJ</given-names></name><name><surname>Lunnon</surname><given-names>MW</given-names></name><name><surname>Laurijssens</surname><given-names>BE</given-names></name><etal/></person-group>. <article-title>Does the unfavorable pharmacokinetic and pharmacodynamic profile of the iNOS inhibitor GW273629 lead to inefficacy in acute migraine?</article-title> <source>J Clin Pharmacol</source> <year>2009</year>; <volume>49</volume>: <fpage>281</fpage>–<lpage>290</lpage>.</citation></ref>
<ref id="bibr31-0333102412475234"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoivik</surname><given-names>HO</given-names></name><name><surname>Laurijssens</surname><given-names>BE</given-names></name><name><surname>Harnisch</surname><given-names>LO</given-names></name><etal/></person-group>. <article-title>Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache</article-title>. <source>Cephalalgia</source> <year>2010</year>; <volume>30</volume>: <fpage>1458</fpage>–<lpage>1467</lpage>.</citation></ref>
<ref id="bibr32-0333102412475234"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dieterle</surname><given-names>A</given-names></name><name><surname>Fischer</surname><given-names>MJ</given-names></name><name><surname>Link</surname><given-names>AS</given-names></name><etal/></person-group>. <article-title>Increase in CGRP- and nNOS-immunoreactive neurons in the rat trigeminal ganglion after infusion of an NO donor</article-title>. <source>Cephalalgia</source> <year>2011</year>; <volume>31</volume>: <fpage>31</fpage>–<lpage>42</lpage>.</citation></ref>
<ref id="bibr33-0333102412475234"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Annedi</surname><given-names>SC</given-names></name><name><surname>Maddaford</surname><given-names>SP</given-names></name><name><surname>Ramnauth</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>3,5-Disubstituted indole derivatives as selective human neuronal nitric oxide synthase (nNOS) inhibitors</article-title>. <source>Bioorg Med Chem Lett</source> <year>2012</year>; <volume>22</volume>: <fpage>1980</fpage>–<lpage>1984</lpage>.</citation></ref>
<ref id="bibr34-0333102412475234"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fullerton</surname><given-names>T</given-names></name><name><surname>Komorowski-Swiatek</surname><given-names>D</given-names></name><name><surname>Forrest</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>The pharmacodynamics of sumatriptan in nitroglycerin-induced headache</article-title>. <source>J Clin Pharmacol</source> <year>1999</year>; <volume>39</volume>: <fpage>17</fpage>–<lpage>29</lpage>.</citation></ref>
<ref id="bibr35-0333102412475234"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iversen</surname><given-names>HK</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name></person-group>. <article-title>Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs</article-title>. <source>Cephalalgia</source> <year>1996</year>; <volume>16</volume>: <fpage>412</fpage>–<lpage>418</lpage>.</citation></ref>
<ref id="bibr36-0333102412475234"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmetterer</surname><given-names>L</given-names></name><name><surname>Wolzt</surname><given-names>M</given-names></name><name><surname>Krejcy</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Cerebral and ocular hemodynamic effects of sumatriptan in the nitroglycerin headache model</article-title>. <source>Clin Pharmacol Ther</source> <year>1996</year>; <volume>60</volume>: <fpage>199</fpage>–<lpage>205</lpage>.</citation></ref>
<ref id="bibr37-0333102412475234"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tvedskov</surname><given-names>JF</given-names></name><name><surname>Iversen</surname><given-names>HK</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Nitroglycerin provocation in normal subjects is not a useful human migraine model?</article-title> <source>Cephalalgia</source> <year>2010</year>; <volume>30</volume>: <fpage>928</fpage>–<lpage>932</lpage>.</citation></ref>
<ref id="bibr38-0333102412475234"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tvedskov</surname><given-names>JF</given-names></name><name><surname>Thomsen</surname><given-names>LL</given-names></name><name><surname>Iversen</surname><given-names>HK</given-names></name><etal/></person-group>. <article-title>The effect of propranolol on glyceryltrinitrate-induced headache and arterial response</article-title>. <source>Cephalalgia</source> <year>2004</year>; <volume>24</volume>: <fpage>1076</fpage>–<lpage>1087</lpage>.</citation></ref>
<ref id="bibr39-0333102412475234"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van der Schueren</surname><given-names>BJ</given-names></name><name><surname>Blanchard</surname><given-names>R</given-names></name><name><surname>Murphy</surname><given-names>MG</given-names></name><etal/></person-group>. <article-title>The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men</article-title>. <source>Br J Clin Pharmacol</source> <year>2011</year>; <volume>71</volume>: <fpage>708</fpage>–<lpage>717</lpage>.</citation></ref>
<ref id="bibr40-0333102412475234"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tvedskov</surname><given-names>JF</given-names></name><name><surname>Tfelt-Hansen</surname><given-names>P</given-names></name><name><surname>Petersen</surname><given-names>KA</given-names></name><etal/></person-group>. <article-title>CGRP receptor antagonist olcegepant (BIBN4096BS) does not prevent glyceryl trinitrate-induced migraine</article-title>. <source>Cephalalgia</source> <year>2010</year>; <volume>30</volume>: <fpage>1346</fpage>–<lpage>1353</lpage>.</citation></ref>
<ref id="bibr41-0333102412475234"><label>41</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Ashina</surname><given-names>M</given-names></name></person-group> <article-title>Human models – screening models</article-title>. In: <person-group person-group-type="editor"><name><surname>Ramadan</surname><given-names>N</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name></person-group> (eds). <source>Innovative drug development for headache disorders</source>, <publisher-loc>Oxford, UK</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>, <year>2008</year>.</citation></ref>
<ref id="bibr42-0333102412475234"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Thomsen</surname><given-names>LL</given-names></name><name><surname>Lassen</surname><given-names>LH</given-names></name><etal/></person-group>. <article-title>The nitric oxide hypothesis of migraine and other vascular headaches</article-title>. <source>Cephalalgia</source> <year>1995</year>; <volume>15</volume>: <fpage>94</fpage>–<lpage>100</lpage>.</citation></ref>
<ref id="bibr43-0333102412475234"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pickering</surname><given-names>GW</given-names></name><name><surname>Hess</surname><given-names>W</given-names></name></person-group>. <article-title>Headache produced by histamine and its mechanism</article-title>. <source>Br J Med</source> <year>1932</year>; <volume>2</volume>: <fpage>1097</fpage>–<lpage>1098</lpage>.</citation></ref>
<ref id="bibr44-0333102412475234"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>D</given-names></name><name><surname>Hough</surname><given-names>H</given-names></name><name><surname>Wolff</surname><given-names>HG</given-names></name></person-group>. <article-title>Experimental studies on headache: Observations on headache produced by histamine</article-title>. <source>Arch NeuroPsych</source> <year>1936</year>; <volume>35</volume>: <fpage>1054</fpage>–<lpage>1069</lpage>.</citation></ref>
<ref id="bibr45-0333102412475234"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Northfield</surname><given-names>DWC</given-names></name></person-group>. <article-title>Some observations on headache</article-title>. <source>Brain</source> <year>1938</year>; <volume>61</volume>: <fpage>133</fpage>–<lpage>162</lpage>.</citation></ref>
<ref id="bibr46-0333102412475234"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sicuteri</surname><given-names>F</given-names></name><name><surname>Ricci</surname><given-names>M</given-names></name><name><surname>Monfardini</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Experimental headache with endogeneous histamine; first results obtained by 48/80, a histamine-liberator drug, in the cephalic and peripheral circulatory systems of man</article-title>. <source>Acta Allergol</source> <year>1957</year>; <volume>11</volume>: <fpage>188</fpage>–<lpage>192</lpage>.</citation></ref>
<ref id="bibr47-0333102412475234"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krabbe</surname><given-names>AA</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name></person-group>. <article-title>Headache provocation by continuous intravenous infusion of histamine. Clinical results and receptor mechanisms</article-title>. <source>Pain</source> <year>1980</year>; <volume>8</volume>: <fpage>253</fpage>–<lpage>259</lpage>.</citation></ref>
<ref id="bibr48-0333102412475234"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lassen</surname><given-names>LH</given-names></name><name><surname>Thomsen</surname><given-names>LL</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name></person-group>. <article-title>Histamine induces migraine via the H1-receptor. Support for the NO hypothesis of migraine</article-title>. <source>Neuroreport</source> <year>1995</year>; <volume>6</volume>: <fpage>1475</fpage>–<lpage>1479</lpage>.</citation></ref>
<ref id="bibr49-0333102412475234"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lassen</surname><given-names>LH</given-names></name><name><surname>Christiansen</surname><given-names>I</given-names></name><name><surname>Iversen</surname><given-names>HK</given-names></name><etal/></person-group>. <article-title>The effect of nitric oxide synthase inhibition on histamine induced headache and arterial dilatation in migraineurs</article-title>. <source>Cephalalgia</source> <year>2003</year>; <volume>23</volume>: <fpage>877</fpage>–<lpage>886</lpage>.</citation></ref>
<ref id="bibr50-0333102412475234"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Burstein</surname><given-names>R</given-names></name><name><surname>Kainz</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Mast cell degranulation activates a pain pathway underlying migraine headache</article-title>. <source>Pain</source> <year>2007</year>; <volume>130</volume>: <fpage>166</fpage>–<lpage>176</lpage>.</citation></ref>
<ref id="bibr51-0333102412475234"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kelley</surname><given-names>NE</given-names></name><name><surname>Tepper</surname><given-names>DE</given-names></name></person-group>. <article-title>Rescue therapy for acute migraine, part 2: Neuroleptics, antihistamines, and others</article-title>. <source>Headache</source> <year>2012</year>; <volume>52</volume>: <fpage>292</fpage>–<lpage>306</lpage>.</citation></ref>
<ref id="bibr52-0333102412475234"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tek</surname><given-names>D</given-names></name><name><surname>Mellon</surname><given-names>M</given-names></name></person-group>. <article-title>The effectiveness of nalbuphine and hydroxyzine for the emergency treatment of severe headache</article-title>. <source>Ann Emerg Med</source> <year>1987</year>; <volume>16</volume>: <fpage>308</fpage>–<lpage>313</lpage>.</citation></ref>
<ref id="bibr53-0333102412475234"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nanda</surname><given-names>RN</given-names></name><name><surname>Arthur</surname><given-names>GP</given-names></name><name><surname>Johnson</surname><given-names>RH</given-names></name><etal/></person-group>. <article-title>Cimetidine in the prophylaxis of migraine</article-title>. <source>Acta Neurol Scand</source> <year>1980</year>; <volume>62</volume>: <fpage>90</fpage>–<lpage>95</lpage>.</citation></ref>
<ref id="bibr54-0333102412475234"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Edvinsson</surname><given-names>L</given-names></name><name><surname>Ekman</surname><given-names>R</given-names></name><name><surname>Jansen</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Peptide-containing nerve fibers in human cerebral arteries: Immunocytochemistry, radioimmunoassay, and <italic>in vitro</italic> pharmacology</article-title>. <source>Ann Neurol</source> <year>1987</year>; <volume>21</volume>: <fpage>431</fpage>–<lpage>437</lpage>.</citation></ref>
<ref id="bibr55-0333102412475234"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname><given-names>I</given-names></name><name><surname>Uddman</surname><given-names>R</given-names></name><name><surname>Hocherman</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Localization and effects of neuropeptide Y, vasoactive intestinal polypeptide, substance P, and calcitonin gene-related peptide in human temporal arteries</article-title>. <source>Ann Neurol</source> <year>1986</year>; <volume>20</volume>: <fpage>496</fpage>–<lpage>501</lpage>.</citation></ref>
<ref id="bibr56-0333102412475234"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goadsby</surname><given-names>PJ</given-names></name><name><surname>Edvinsson</surname><given-names>L</given-names></name><name><surname>Ekman</surname><given-names>R</given-names></name></person-group>. <article-title>Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system</article-title>. <source>Ann Neurol</source> <year>1988</year>; <volume>23</volume>: <fpage>193</fpage>–<lpage>196</lpage>.</citation></ref>
<ref id="bibr57-0333102412475234"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goadsby</surname><given-names>PJ</given-names></name><name><surname>Edvinsson</surname><given-names>L</given-names></name><name><surname>Ekman</surname><given-names>R</given-names></name></person-group>. <article-title>Vasoactive peptide release in the extracerebral circulation of humans during migraine headache</article-title>. <source>Ann Neurol</source> <year>1990</year>; <volume>28</volume>: <fpage>183</fpage>–<lpage>187</lpage>.</citation></ref>
<ref id="bibr58-0333102412475234"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ashina</surname><given-names>M</given-names></name><name><surname>Bendtsen</surname><given-names>L</given-names></name><name><surname>Jensen</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks</article-title>. <source>Pain</source> <year>2000</year>; <volume>86</volume>: <fpage>133</fpage>–<lpage>138</lpage>.</citation></ref>
<ref id="bibr59-0333102412475234"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tvedskov</surname><given-names>JF</given-names></name><name><surname>Lipka</surname><given-names>K</given-names></name><name><surname>Ashina</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>No increase of calcitonin gene-related peptide in jugular blood during migraine</article-title>. <source>Ann Neurol</source> <year>2005</year>; <volume>58</volume>: <fpage>561</fpage>–<lpage>568</lpage>.</citation></ref>
<ref id="bibr60-0333102412475234"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lassen</surname><given-names>LH</given-names></name><name><surname>Haderslev</surname><given-names>PA</given-names></name><name><surname>Jacobsen</surname><given-names>VB</given-names></name><etal/></person-group>. <article-title>CGRP may play a causative role in migraine</article-title>. <source>Cephalalgia</source> <year>2002</year>; <volume>22</volume>: <fpage>54</fpage>–<lpage>61</lpage>.</citation></ref>
<ref id="bibr61-0333102412475234"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>JM</given-names></name><name><surname>Hauge</surname><given-names>AW</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura</article-title>. <source>Cephalalgia</source> <year>2010</year>; <volume>30</volume>: <fpage>1179</fpage>–<lpage>1186</lpage>.</citation></ref>
<ref id="bibr62-0333102412475234"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lassen</surname><given-names>LH</given-names></name><name><surname>Jacobsen</surname><given-names>VB</given-names></name><name><surname>Haderslev</surname><given-names>PA</given-names></name><etal/></person-group>. <article-title>Involvement of calcitonin gene-related peptide in migraine: Regional cerebral blood flow and blood flow velocity in migraine patients</article-title>. <source>J Headache Pain</source> <year>2008</year>; <volume>9</volume>: <fpage>151</fpage>–<lpage>157</lpage>.</citation></ref>
<ref id="bibr63-0333102412475234"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>KA</given-names></name><name><surname>Lassen</surname><given-names>LH</given-names></name><name><surname>Birk</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation</article-title>. <source>Clin Pharmacol Ther</source> <year>2005</year>; <volume>77</volume>: <fpage>202</fpage>–<lpage>213</lpage>.</citation></ref>
<ref id="bibr64-0333102412475234"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Diener</surname><given-names>HC</given-names></name><name><surname>Husstedt</surname><given-names>IW</given-names></name><etal/></person-group>. <article-title>Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine</article-title>. <source>N Engl J Med</source> <year>2004</year>; <volume>350</volume>: <fpage>1104</fpage>–<lpage>1110</lpage>.</citation></ref>
<ref id="bibr65-0333102412475234"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>TW</given-names></name><name><surname>Mannix</surname><given-names>LK</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine</article-title>. <source>Neurology</source> <year>2008</year>; <volume>70</volume>: <fpage>1304</fpage>–<lpage>1312</lpage>.</citation></ref>
<ref id="bibr66-0333102412475234"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>TW</given-names></name><name><surname>Ferrari</surname><given-names>MD</given-names></name><name><surname>Dodick</surname><given-names>DW</given-names></name><etal/></person-group>. <article-title>Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial</article-title>. <source>Lancet</source> <year>2008</year>; <volume>372</volume>: <fpage>2115</fpage>–<lpage>2123</lpage>.</citation></ref>
<ref id="bibr67-0333102412475234"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hewitt</surname><given-names>DJ</given-names></name><name><surname>Aurora</surname><given-names>SK</given-names></name><name><surname>Dodick</surname><given-names>DW</given-names></name><etal/></person-group>. <article-title>Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine</article-title>. <source>Cephalalgia</source> <year>2011</year>; <volume>31</volume>: <fpage>712</fpage>–<lpage>722</lpage>.</citation></ref>
<ref id="bibr68-0333102412475234"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asghar</surname><given-names>MS</given-names></name><name><surname>Hansen</surname><given-names>AE</given-names></name><name><surname>Kapijimpanga</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers</article-title>. <source>Neurology</source> <year>2010</year>; <volume>75</volume>: <fpage>1520</fpage>–<lpage>1526</lpage>.</citation></ref>
<ref id="bibr69-0333102412475234"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iversen</surname><given-names>HK</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name></person-group>. <article-title>Nitroglycerin-induced headache is not dependent on histamine release: Support for a direct nociceptive action of nitric oxide</article-title>. <source>Cephalalgia</source> <year>1994</year>; <volume>14</volume>: <fpage>437</fpage>–<lpage>442</lpage>.</citation></ref>
<ref id="bibr70-0333102412475234"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kruuse</surname><given-names>C</given-names></name><name><surname>Thomsen</surname><given-names>LL</given-names></name><name><surname>Jacobsen</surname><given-names>TB</given-names></name><etal/></person-group>. <article-title>The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects</article-title>. <source>J Cereb Blood Flow Metab</source> <year>2002</year>; <volume>22</volume>: <fpage>1124</fpage>–<lpage>1131</lpage>.</citation></ref>
<ref id="bibr71-0333102412475234"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kruuse</surname><given-names>C</given-names></name><name><surname>Thomsen</surname><given-names>LL</given-names></name><name><surname>Birk</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Migraine can be induced by sildenafil without changes in middle cerebral artery diameter</article-title>. <source>Brain</source> <year>2003</year>; <volume>126</volume>: <fpage>241</fpage>–<lpage>247</lpage>. <comment>**<bold>Based on a provocation experiment with sildenafil, it was reported that migraine may be induced via a cGMP-dependent mechanism, without initial dilation of the middle cerebral artery.</bold></comment>.</citation></ref>
<ref id="bibr72-0333102412475234"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kruuse</surname><given-names>C</given-names></name><name><surname>Hansen</surname><given-names>AE</given-names></name><name><surname>Larsson</surname><given-names>HB</given-names></name><etal/></person-group>. <article-title>Cerebral haemodynamic response or excitability is not affected by sildenafil</article-title>. <source>J Cereb Blood Flow Metab</source> <year>2009</year>; <volume>29</volume>: <fpage>830</fpage>–<lpage>839</lpage>.</citation></ref>
<ref id="bibr73-0333102412475234"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kruuse</surname><given-names>C</given-names></name><name><surname>Lassen</surname><given-names>LH</given-names></name><name><surname>Iversen</surname><given-names>HK</given-names></name><etal/></person-group>. <article-title>Dipyridamole may induce migraine in patients with migraine without aura</article-title>. <source>Cephalalgia</source> <year>2006</year>; <volume>26</volume>: <fpage>925</fpage>–<lpage>933</lpage>.</citation></ref>
<ref id="bibr74-0333102412475234"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Birk</surname><given-names>S</given-names></name><name><surname>Kruuse</surname><given-names>C</given-names></name><name><surname>Petersen</surname><given-names>KA</given-names></name><etal/></person-group>. <article-title>The headache-inducing effect of cilostazol in human volunteers</article-title>. <source>Cephalalgia</source> <year>2006</year>; <volume>26</volume>: <fpage>1304</fpage>–<lpage>1309</lpage>.</citation></ref>
<ref id="bibr75-0333102412475234"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dinn</surname><given-names>RB</given-names></name><name><surname>Wall</surname><given-names>M</given-names></name></person-group>. <article-title>Tadalafil associated with typical migraine aura without headache</article-title>. <source>Cephalalgia</source> <year>2006</year>; <volume>26</volume>: <fpage>1344</fpage>–<lpage>1346</lpage>.</citation></ref>
<ref id="bibr76-0333102412475234"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jansen-Olesen</surname><given-names>I</given-names></name><name><surname>Gulbenkian</surname><given-names>S</given-names></name><name><surname>Engel</surname><given-names>U</given-names></name><etal/></person-group>. <article-title>Peptidergic and non-peptidergic innervation and vasomotor responses of human lenticulostriate and posterior cerebral arteries</article-title>. <source>Peptides</source> <year>2004</year>; <volume>25</volume>: <fpage>2105</fpage>–<lpage>2114</lpage>.</citation></ref>
<ref id="bibr77-0333102412475234"><label>77</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baeres</surname><given-names>FM</given-names></name><name><surname>Moller</surname><given-names>M</given-names></name></person-group>. <article-title>Origin of PACAP-immunoreactive nerve fibers innervating the subarachnoidal blood vessels of the rat brain</article-title>. <source>J Cereb Blood Flow Metab</source> <year>2004</year>; <volume>24</volume>: <fpage>628</fpage>–<lpage>635</lpage>.</citation></ref>
<ref id="bibr78-0333102412475234"><label>78</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gulbenkian</surname><given-names>S</given-names></name><name><surname>Uddman</surname><given-names>R</given-names></name><name><surname>Edvinsson</surname><given-names>L</given-names></name></person-group>. <article-title>Neuronal messengers in the human cerebral circulation</article-title>. <source>Peptides</source> <year>2001</year>; <volume>22</volume>: <fpage>995</fpage>–<lpage>1007</lpage>.</citation></ref>
<ref id="bibr79-0333102412475234"><label>79</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hosoya</surname><given-names>M</given-names></name><name><surname>Onda</surname><given-names>H</given-names></name><name><surname>Ogi</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Molecular cloning and functional expression of rat cDNAs encoding the receptor for pituitary adenylate cyclase activating polypeptide (PACAP)</article-title>. <source>Biochem Biophys Res Commun</source> <year>1993</year>; <volume>194</volume>: <fpage>133</fpage>–<lpage>143</lpage>.</citation></ref>
<ref id="bibr80-0333102412475234"><label>80</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lutz</surname><given-names>EM</given-names></name><name><surname>Sheward</surname><given-names>WJ</given-names></name><name><surname>West</surname><given-names>KM</given-names></name><etal/></person-group>. <article-title>The VIP2 receptor: Molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide</article-title>. <source>FEBS Lett</source> <year>1993</year>; <volume>334</volume>: <fpage>3</fpage>–<lpage>8</lpage>.</citation></ref>
<ref id="bibr81-0333102412475234"><label>81</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harmar</surname><given-names>AJ</given-names></name><name><surname>Arimura</surname><given-names>A</given-names></name><name><surname>Gozes</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide</article-title>. <source>Pharmacol Rev</source> <year>1998</year>; <volume>50</volume>: <fpage>265</fpage>–<lpage>270</lpage>.</citation></ref>
<ref id="bibr82-0333102412475234"><label>82</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>JM</given-names></name><name><surname>Sitarz</surname><given-names>J</given-names></name><name><surname>Birk</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers</article-title>. <source>Cephalalgia</source> <year>2006</year>; <volume>26</volume>: <fpage>992</fpage>–<lpage>1003</lpage>.</citation></ref>
<ref id="bibr83-0333102412475234"><label>83</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rahmann</surname><given-names>A</given-names></name><name><surname>Wienecke</surname><given-names>T</given-names></name><name><surname>Hansen</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine</article-title>. <source>Cephalalgia</source> <year>2008</year>; <volume>28</volume>: <fpage>226</fpage>–<lpage>236</lpage>.</citation></ref>
<ref id="bibr84-0333102412475234"><label>84</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>J</given-names></name><name><surname>Rahmann</surname><given-names>A</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><etal/></person-group> <article-title>Vasoactive intestinal polypeptide is unlikely to be a target for headache and migraine treatment</article-title>. In: <person-group person-group-type="editor"><name><surname>Ramadan</surname><given-names>N</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name></person-group> (eds). <source>Innovative drug development for headache disorders</source>, <publisher-loc>Oxford</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>, <year>2008</year>.</citation></ref>
<ref id="bibr85-0333102412475234"><label>85</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schytz</surname><given-names>HW</given-names></name><name><surname>Birk</surname><given-names>S</given-names></name><name><surname>Wienecke</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>PACAP38 induces migraine-like attacks in patients with migraine without aura</article-title>. <source>Brain</source> <year>2009</year>; <volume>132</volume>: <fpage>16</fpage>–<lpage>25</lpage>. <comment>**<bold>Pituitary adenylate cyclase activating polypeptide-38 (PACAP38) infusion caused headache and vasodilation in healthy subjects and migraine patients as well as migraine-like attacks in patients with migraine without aura.</bold></comment>.</citation></ref>
<ref id="bibr86-0333102412475234"><label>86</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amin</surname><given-names>FM</given-names></name><name><surname>Asghar</surname><given-names>MS</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers</article-title>. <source>Cephalalgia</source> <year>2012</year>; <volume>32</volume>: <fpage>140</fpage>–<lpage>149</lpage>.</citation></ref>
<ref id="bibr87-0333102412475234"><label>87</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schytz</surname><given-names>HW</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Ashina</surname><given-names>M</given-names></name></person-group>. <article-title>The PACAP receptor: A novel target for migraine treatment</article-title>. <source>Neurotherapeutics</source> <year>2010</year>; <volume>7</volume>: <fpage>191</fpage>–<lpage>196</lpage>.</citation></ref>
<ref id="bibr88-0333102412475234"><label>88</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tuka</surname><given-names>B</given-names></name><name><surname>Helyes</surname><given-names>Z</given-names></name><name><surname>Markovics</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Peripheral and central alterations of pituitary adenylate cyclase activating polypeptide-like immunoreactivity in the rat in response to activation of the trigeminovascular system</article-title>. <source>Peptides</source> <year>2012</year>; <volume>33</volume>: <fpage>307</fpage>–<lpage>316</lpage>.</citation></ref>
<ref id="bibr89-0333102412475234"><label>89</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baun</surname><given-names>M</given-names></name><name><surname>Pedersen</surname><given-names>MH</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Dural mast cell degranulation is a putative mechanism for headache induced by PACAP-38</article-title>. <source>Cephalalgia</source> <year>2012</year>; <volume>32</volume>: <fpage>337</fpage>–<lpage>345</lpage>.</citation></ref>
<ref id="bibr90-0333102412475234"><label>90</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Theoharides</surname><given-names>TC</given-names></name><name><surname>Donelan</surname><given-names>J</given-names></name><name><surname>Kandere-Grzybowska</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>The role of mast cells in migraine pathophysiology</article-title>. <source>Brain Res Brain Res Rev</source> <year>2005</year>; <volume>49</volume>: <fpage>65</fpage>–<lpage>76</lpage>.</citation></ref>
<ref id="bibr91-0333102412475234"><label>91</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wienecke</surname><given-names>T</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Oturai</surname><given-names>PS</given-names></name><etal/></person-group>. <article-title>Prostaglandin E2 (PGE2) induces headache in healthy subjects</article-title>. <source>Cephalalgia</source> <year>2009</year>; <volume>29</volume>: <fpage>509</fpage>–<lpage>519</lpage>.</citation></ref>
<ref id="bibr92-0333102412475234"><label>92</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wienecke</surname><given-names>T</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Ashina</surname><given-names>M</given-names></name></person-group>. <article-title>Prostaglandin I(2) (epoprostenol) triggers migraine-like attacks in migraineurs</article-title>. <source>Cephalalgia</source> <year>2010</year>; <volume>30</volume>: <fpage>179</fpage>–<lpage>190</lpage>.</citation></ref>
<ref id="bibr93-0333102412475234"><label>93</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wienecke</surname><given-names>T</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Ashina</surname><given-names>M</given-names></name></person-group>. <article-title>Discrepancy between strong cephalic arterial dilatation and mild headache caused by prostaglandin D (PGD)</article-title>. <source>Cephalalgia</source> <year>2011</year>; <volume>31</volume>: <fpage>65</fpage>–<lpage>76</lpage>.</citation></ref>
<ref id="bibr94-0333102412475234"><label>94</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wienecke</surname><given-names>T</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Oturai</surname><given-names>PS</given-names></name><etal/></person-group>. <article-title>Prostacyclin (epoprostenol) induces headache in healthy subjects</article-title>. <source>Pain</source> <year>2008</year>; <volume>139</volume>: <fpage>106</fpage>–<lpage>116</lpage>.</citation></ref>
<ref id="bibr95-0333102412475234"><label>95</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Antonova</surname><given-names>M</given-names></name><name><surname>Wienecke</surname><given-names>T</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Prostaglandin E2 induces immediate migraine-like attack in migraine patients without aura</article-title>. <source>Cephalalgia</source> <year>2012</year>; <volume>32</volume>: <fpage>822</fpage>–<lpage>833</lpage>. <comment>**<bold>In a randomized, blinded crossover study in patients with migraine without aura, infusion of prostaglandin E(2) (PGE2) induced migraine-like attacks during and immediately after infusion, in contrast with previous provocation studies. PGE2 may be one of the important final products involved in the generation of migraine attacks.</bold></comment>.</citation></ref>
<ref id="bibr96-0333102412475234"><label>96</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hata</surname><given-names>AN</given-names></name><name><surname>Breyer</surname><given-names>RM</given-names></name></person-group>. <article-title>Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulation</article-title>. <source>Pharmacol Ther</source> <year>2004</year>; <volume>103</volume>: <fpage>147</fpage>–<lpage>166</lpage>.</citation></ref>
<ref id="bibr97-0333102412475234"><label>97</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Antonova</surname><given-names>M</given-names></name><name><surname>Wienecke</surname><given-names>T</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Pro-inflammatory and vasoconstricting prostanoid PGF2alpha causes no headache in man</article-title>. <source>Cephalalgia</source> <year>2011</year>; <volume>31</volume>: <fpage>1532</fpage>–<lpage>1541</lpage>.</citation></ref>
<ref id="bibr98-0333102412475234"><label>98</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Antonova</surname><given-names>M</given-names></name><name><surname>Wienecke</surname><given-names>T</given-names></name><name><surname>Maubach</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the prostaglandin E2 human model of headache</article-title>. <source>J Headache Pain</source> <year>2011</year>; <volume>12</volume>: <fpage>551</fpage>–<lpage>559</lpage>.</citation></ref>
<ref id="bibr99-0333102412475234"><label>99</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Larsen</surname><given-names>B</given-names></name><name><surname>Lauritzen</surname><given-names>M</given-names></name></person-group>. <article-title>Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine</article-title>. <source>Ann Neurol</source> <year>1981</year>; <volume>9</volume>: <fpage>344</fpage>–<lpage>352</lpage>.</citation></ref>
<ref id="bibr100-0333102412475234"><label>100</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leão</surname><given-names>AAP</given-names></name></person-group>. <article-title>Spreading depression of activity in the cerebral cortex</article-title>. <source>J Neurophysiol</source> <year>1944</year>; <volume>7</volume>: <fpage>359</fpage>–<lpage>390</lpage>.</citation></ref>
<ref id="bibr101-0333102412475234"><label>101</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Noseda</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Activation of meningeal nociceptors by cortical spreading depression: Implications for migraine with aura</article-title>. <source>J Neurosci</source> <year>2010</year>; <volume>30</volume>: <fpage>8807</fpage>–<lpage>8814</lpage>.</citation></ref>
<ref id="bibr102-0333102412475234"><label>102</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Kainz</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Activation of central trigeminovascular neurons by cortical spreading depression</article-title>. <source>Ann Neurol</source> <year>2011</year>; <volume>69</volume>: <fpage>855</fpage>–<lpage>865</lpage>.</citation></ref>
<ref id="bibr103-0333102412475234"><label>103</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bolay</surname><given-names>H</given-names></name><name><surname>Reuter</surname><given-names>U</given-names></name><name><surname>Dunn</surname><given-names>AK</given-names></name><etal/></person-group>. <article-title>Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model</article-title>. <source>Nat Med</source> <year>2002</year>; <volume>8</volume>: <fpage>136</fpage>–<lpage>142</lpage>.</citation></ref>
<ref id="bibr104-0333102412475234"><label>104</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Afridi</surname><given-names>S</given-names></name><name><surname>Kaube</surname><given-names>H</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name></person-group>. <article-title>Occipital activation in glyceryl trinitrate induced migraine with visual aura</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <year>2005</year>; <volume>76</volume>: <fpage>1158</fpage>–<lpage>1160</lpage>.</citation></ref>
<ref id="bibr105-0333102412475234"><label>105</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Christiansen</surname><given-names>I</given-names></name><name><surname>Thomsen</surname><given-names>LL</given-names></name><name><surname>Daugaard</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura</article-title>. <source>Cephalalgia</source> <year>1999</year>; <volume>19</volume>: <fpage>660</fpage>–<lpage>667</lpage>. <comment>discussion 626</comment>.</citation></ref>
<ref id="bibr106-0333102412475234"><label>106</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Welch</surname><given-names>KM</given-names></name><name><surname>Aurora</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Functional MRI-BOLD of visually triggered headache in patients with migraine</article-title>. <source>Arch Neurol</source> <year>1999</year>; <volume>56</volume>: <fpage>548</fpage>–<lpage>554</lpage>.</citation></ref>
<ref id="bibr107-0333102412475234"><label>107</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hadjikhani</surname><given-names>N</given-names></name><name><surname>Sanchez Del Rio</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>O</given-names></name><etal/></person-group>. <article-title>Mechanisms of migraine aura revealed by functional MRI in human visual cortex</article-title>. <source>Proc Natl Acad Sci USA</source> <year>2001</year>; <volume>98</volume>: <fpage>4687</fpage>–<lpage>4692</lpage>.</citation></ref>
<ref id="bibr108-0333102412475234"><label>108</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dreier</surname><given-names>JP</given-names></name><name><surname>Kleeberg</surname><given-names>J</given-names></name><name><surname>Petzold</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Endothelin-1 potently induces Leao's cortical spreading depression in vivo in the rat: A model for an endothelial trigger of migrainous aura?</article-title> <source>Brain</source> <year>2002</year>; <volume>125</volume>: <fpage>102</fpage>–<lpage>112</lpage>.</citation></ref>
<ref id="bibr109-0333102412475234"><label>109</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nozari</surname><given-names>A</given-names></name><name><surname>Dilekoz</surname><given-names>E</given-names></name><name><surname>Sukhotinsky</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Microemboli may link spreading depression, migraine aura, and patent foramen ovale</article-title>. <source>Ann Neurol</source> <year>2010</year>; <volume>67</volume>: <fpage>221</fpage>–<lpage>229</lpage>.</citation></ref>
<ref id="bibr110-0333102412475234"><label>110</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Fusco</surname><given-names>M</given-names></name><name><surname>Marconi</surname><given-names>R</given-names></name><name><surname>Silvestri</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2</article-title>. <source>Nat Genet</source> <year>2003</year>; <volume>33</volume>: <fpage>192</fpage>–<lpage>196</lpage>.</citation></ref>
<ref id="bibr111-0333102412475234"><label>111</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ophoff</surname><given-names>RA</given-names></name><name><surname>Terwindt</surname><given-names>GM</given-names></name><name><surname>Vergouwe</surname><given-names>MN</given-names></name><etal/></person-group>. <article-title>Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4</article-title>. <source>Cell</source> <year>1996</year>; <volume>87</volume>: <fpage>543</fpage>–<lpage>552</lpage>.</citation></ref>
<ref id="bibr112-0333102412475234"><label>112</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dichgans</surname><given-names>M</given-names></name><name><surname>Freilinger</surname><given-names>T</given-names></name><name><surname>Eckstein</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine</article-title>. <source>Lancet</source> <year>2005</year>; <volume>366</volume>: <fpage>371</fpage>–<lpage>377</lpage>.</citation></ref>
<ref id="bibr113-0333102412475234"><label>113</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van den Maagdenberg</surname><given-names>AM</given-names></name><name><surname>Pietrobon</surname><given-names>D</given-names></name><name><surname>Pizzorusso</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression</article-title>. <source>Neuron</source> <year>2004</year>; <volume>41</volume>: <fpage>701</fpage>–<lpage>710</lpage>.</citation></ref>
<ref id="bibr114-0333102412475234"><label>114</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leo</surname><given-names>L</given-names></name><name><surname>Gherardini</surname><given-names>L</given-names></name><name><surname>Barone</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Increased susceptibility to cortical spreading depression in the mouse model of familial hemiplegic migraine type 2</article-title>. <source>PLoS Genet</source> <year>2011</year>; <volume>7</volume>: <fpage>e1002129</fpage>–<lpage>e1002129</lpage>.</citation></ref>
<ref id="bibr115-0333102412475234"><label>115</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van de Ven</surname><given-names>RC</given-names></name><name><surname>Kaja</surname><given-names>S</given-names></name><name><surname>Plomp</surname><given-names>JJ</given-names></name><etal/></person-group>. <article-title>Genetic models of migraine</article-title>. <source>Arch Neurol</source> <year>2007</year>; <volume>64</volume>: <fpage>643</fpage>–<lpage>646</lpage>.</citation></ref>
<ref id="bibr116-0333102412475234"><label>116</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>J</given-names></name><name><surname>Thomsen</surname><given-names>LL</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Calcitonin gene-related peptide does not cause the familial hemiplegic migraine phenotype</article-title>. <source>Neurology</source> <year>2008</year>; <volume>71</volume>: <fpage>841</fpage>–<lpage>847</lpage>. <comment>**<bold>Infusion of CGRP did not cause migraine-like attacks in patients with familial hemiplegic migraine, as characteristically seen in migraine patients without aura. This suggests that the pathophysiologic pathways underlying migraine headache in FHM may be different from the common types of migraine.</bold></comment>.</citation></ref>
<ref id="bibr117-0333102412475234"><label>117</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>JM</given-names></name><name><surname>Thomsen</surname><given-names>LL</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Calcitonin gene-related peptide does not cause migraine attacks in patients with familial hemiplegic migraine</article-title>. <source>Headache</source> <year>2011</year>; <volume>51</volume>: <fpage>544</fpage>–<lpage>553</lpage>.</citation></ref>
<ref id="bibr118-0333102412475234"><label>118</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>J</given-names></name><name><surname>Thomsen</surname><given-names>LL</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Coexisting typical migraine in familial hemiplegic migraine</article-title>. <source>Neurology</source> <year>2010</year>; <volume>74</volume>: <fpage>594</fpage>–<lpage>600</lpage>.</citation></ref>
<ref id="bibr119-0333102412475234"><label>119</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kelman</surname><given-names>L</given-names></name></person-group>. <article-title>Pain characteristics of the acute migraine attack</article-title>. <source>Headache</source> <year>2006</year>; <volume>46</volume>: <fpage>942</fpage>–<lpage>953</lpage>.</citation></ref>
<ref id="bibr120-0333102412475234"><label>120</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Bousser</surname><given-names>MG</given-names></name><name><surname>Diener</surname><given-names>HC</given-names></name><etal/></person-group>. <article-title>New appendix criteria open for a broader concept of chronic migraine</article-title>. <source>Cephalalgia</source> <year>2006</year>; <volume>26</volume>: <fpage>742</fpage>–<lpage>746</lpage>.</citation></ref>
<ref id="bibr121-0333102412475234"><label>121</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>JM</given-names></name></person-group>. <article-title>Familial hemiplegic migraine</article-title>. <source>Dan Med Bull</source> <year>2010</year>; <volume>57</volume>: <fpage>B4183</fpage>–<lpage>B4183</lpage>.</citation></ref>
<ref id="bibr122-0333102412475234"><label>122</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>J</given-names></name><name><surname>Thomsen</surname><given-names>LL</given-names></name><name><surname>Marconi</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Familial hemiplegic migraine type 2 does not share hypersensitivity to nitric oxide with common types of migraine</article-title>. <source>Cephalalgia</source> <year>2008</year>; <volume>28</volume>: <fpage>367</fpage>–<lpage>375</lpage>.</citation></ref>
<ref id="bibr123-0333102412475234"><label>123</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>J</given-names></name><name><surname>Thomsen</surname><given-names>LL</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Familial hemiplegic migraine type 1 shows no hypersensitivity to nitric oxide</article-title>. <source>Cephalalgia</source> <year>2008</year>; <volume>28</volume>: <fpage>496</fpage>–<lpage>505</lpage>.</citation></ref>
<ref id="bibr124-0333102412475234"><label>124</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lassen</surname><given-names>LH</given-names></name><name><surname>Heinig</surname><given-names>JH</given-names></name><name><surname>Oestergaard</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Histamine inhalation is a specific but insensitive laboratory test for migraine</article-title>. <source>Cephalalgia</source> <year>1996</year>; <volume>16</volume>: <fpage>550</fpage>–<lpage>553</lpage>.</citation></ref>
<ref id="bibr125-0333102412475234"><label>125</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kruuse</surname><given-names>C</given-names></name><name><surname>Jacobsen</surname><given-names>TB</given-names></name><name><surname>Lassen</surname><given-names>LH</given-names></name><etal/></person-group>. <article-title>Dipyridamole dilates large cerebral arteries concomitant to headache induction in healthy subjects</article-title>. <source>J Cereb Blood Flow Metab</source> <year>2000</year>; <volume>20</volume>: <fpage>1372</fpage>–<lpage>1379</lpage>.</citation></ref>
<ref id="bibr126-0333102412475234"><label>126</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Birk</surname><given-names>S</given-names></name><name><surname>Sitarz</surname><given-names>JT</given-names></name><name><surname>Petersen</surname><given-names>KA</given-names></name><etal/></person-group>. <article-title>The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers</article-title>. <source>Regul Pept</source> <year>2007</year>; <volume>140</volume>: <fpage>185</fpage>–<lpage>191</lpage>.</citation></ref>
<ref id="bibr127-0333102412475234"><label>127</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Tfelt-Hansen</surname><given-names>P</given-names></name><name><surname>Ashina</surname><given-names>M</given-names></name></person-group>. <article-title>Finding new drug targets for the treatment of migraine attacks</article-title>. <source>Cephalalgia</source> <year>2009</year>; <volume>29</volume>: <fpage>909</fpage>–<lpage>920</lpage>.</citation></ref>
</ref-list>
</back>
</article>